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Osteosarcoma metastasizes to the lung, and there is a link between the predominance
of tumor promoting immunosuppressive M2 macrophages in the metastases and poor
patient survival. By contrast, M1 macrophage predominance correlates with longer
survival. M2 macrophages can be induced by various stimuli in the tumor
microenvironment, including exosomes, which are 40- to 150-nm vesicles that are
involved in intercellular communication and contribute to tumor progression and
immune evasion. Recognizing that tumor cells can influence the tumor
microenvironment to make it more permissive and because of the link between M2
dominance and curtailed patient survival, we evaluated the effect of exosomes from
non-metastatic K7 and Dunn osteosarcoma cells and the metastatic sublines K7M3
and DLM8 on macrophage phenotype and function. Incubating MHS mouse alveolar
macrophages with K7M3 and DLM8 exosomes induced expression of IL10, TGFB2,
and CCL22 mRNA (markers of M2 macrophages) and decreased phagocytosis,
efferocytosis, and macrophage-mediated tumor cell killing. In contrast, exosomes from
non-metastatic K7 or Dunn cells did not inhibit phagocytosis, efferocytosis, and
macrophage-mediated cytotoxicity or induce increased expression of IL10, TGFB2 or
CCL22 mRNA. In addition, metastatic osteosarcoma cell exosomes significantly
increased the secretion of TGFB2, a key signaling pathway associated with tumormediated immune suppression. Finally, the inhibition of TGFB2 reversed the
suppressive activity of alveolar macrophages exposed to metastatic osteosarcoma cell
exosomes. Our data suggest that the exosomes from metastatic osteosarcoma cells
can modulate cellular signaling of tumor-associated macrophages, thereby promoting
the M2 phenotype and creating an immunosuppressive, tumor-promoting
microenvironment through the production of TGFB2.
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CHAPTER ONE: INTRODUCTION

1.1 Osteosarcoma

1.1.1: Overview
Despite advances in both chemotherapy and therapeutic interventions in recent
years, there remains an urgent need to understand and investigate pediatric cancers in
order to better improve patient outcome and survival. Osteosarcoma is the most
common primary malignancy of bone in the pediatric population [1]. There is an initial
peak in incidence in children between the ages of ten and fourteen years old as well as
a second smaller peak in incidence in the elderly population between the ages of sixty
and eighty years old [2]. Osteosarcoma most commonly presents in the metaphyses of
the long bones which includes the distal femur, proximal tibia, and the proximal
humerus [2]. Other less common sites include the pelvis, jaw and the skull [2].
Osteosarcoma also has a high propensity to metastasize almost exclusively to the lung
and is typically diagnosed through the use of a physical exam and imaging tests which
can include an X-ray, a CT-scan, an MRI, a PET scan or a bone scan [2]. Additionally,
either a needle or surgical biopsy can be performed to determine if the cells within a
suspicious mass are cancerous or not, as well as to assess the grade and
aggressiveness of the tumor.
There are a variety of risk factors that have been associated with osteosarcoma.
Rapid bone turnover, growth and taller stature have been correlated with the increased
occurrence of osteosarcoma [3]. There is a slightly higher incidence in males than
females which also corresponds to the intrinsic differences in skeletal growth rates [3].
There are a number of diseases and heritable syndromes that have also been
1

correlated with the occurrence of osteosarcoma that include Paget’s disease, LiFraumeni syndrome, mutations in the DNA helicase family as well as germline
mutations in the RB1 tumor suppressor gene [3].

1.1.2: Standard Treatment Practices
The main course of treatment for patients with osteosarcoma is surgery.
Although curative in a number of cases, survival for patients treated with surgery alone
is very low at approximately fifteen to seventeen percent [4, 5]. Current treatment
regimens include multi-agent chemotherapy as well as surgical resection. The
chemotherapeutic agents most commonly used to treat osteosarcoma are doxorubicin
combined with cisplatin with or without methotrexate [2]. In patients with non-metastatic
disease, the combination of surgery and neoadjuvant chemotherapy is curative in about
seventy percent of patients [3]. Survival for patients with metastatic disease is far more
dismal however and has remained at about twenty percent and has not changed
significantly over the past fifty years [4, 6]. Current efforts to better understand
osteosarcoma in order to reveal new therapeutic targets are currently underway and
include targeting the bone microenvironment, receptor tyrosine kinases and
intracellular signaling pathways, as well as immune targeted therapies.

1.1.3. Development and Molecular Characteristics
The bone microenvironment is unique in that its main role is to support and
protect the vital organs and muscles in the body. It is a specialized connective tissue
that is composed of two main cell types which both form and remodel bone.
Osteoblasts are a type of mesenchymal cell that form bone and are located at
periosteal surfaces, which are a thick membrane of fibrous connective tissue that wraps
2

around the surface of the majority of bones within the body [3]. The second cell of
interest in the bone is an osteoclast, which is a highly specialized macrophage that is
specific to the bone microenvironment [3]. The main role of an osteoclast is bone
resorption and remodeling. Osteoclasts are derived from a monocytic lineage and are
capable of phagocytosis just like macrophages. Osteosarcoma is a mesenchymal
tumor that is histologically characterized by the presence of malignant mesenchymal
cells and the overproduction of bone stroma [3]. There are several distinct histological
subtypes that are known as chondroblastic, fibroblastic, osteoblastic, and telangiectatic
osteosarcoma [2]. The treatments and biological behaviors of these subtypes are
similar though and it is currently unclear as to how the different histological subtypes
contribute to tumor development and progression. Additionally, osteosarcoma can also
present as either osteoblastic or osteolytic, in which the tumor presents as bone
forming or destructive to the surrounding bone tissue [2].
The mechanisms underlying osteosarcoma development are complex, but there
has been significant progress towards a better understanding of the process in recent
years. The cell of origin for the development of osteosarcoma is highly debatable and
was previously assumed to lie in the cells committed to the bone lineage, namely the
osteoblast and the pre-osteoblastic cells, but in recent years there has been another
cell population of interest that has begun to receive attention [1]. It has been suggested
that the transforming event that leads to the development of osteosarcoma actually
occurs in multipotent mesenchymal stem cells, which would then yield a karyotypic
complexity that would thus drive them down bone-differentiation lineages and explain
the genetic heterogeneity that presents in the fully developed tumor [1]. Regardless, it
has been accepted that the development of osteosarcoma is related to bone in some
form. The development of osteosarcoma correlates with normal phases of skeletal
3

development and commonly presents along growth plates of the appendicular skeleton,
further supporting the idea that the development of osteosarcoma is indeed related to
bone [7].
Osteosarcoma is a highly heterogeneous malignancy and there has been no
discovery of a main motivating genetic driver thus far. The genetics of osteosarcoma
are complex, but in recent years, it has been suggested that the complexity of the
osteosarcoma genome and the extent of somatic mutations are similar to common
forms of adult cancer such as breast cancer [8]. Osteosarcoma has one of the highest
somatic mutations rate among childhood tumors and is best characterized by its
disorganized genome [8]. In contrast, Ewing’s sarcoma has a very low frequency of
somatic mutations due to the fact that is a cancer driven mainly by a fusion gene [8]. In
osteosarcoma, there have been a number of drivers that have been identified which
include both oncogenes and tumor suppressor genes. Additionally, osteosarcoma
presents with significant aneuploidy as well as massive disruptions in the control of
chromosomal structure [1, 3, 8].
Comprehensive and genomic analyses are difficult to perform due to the rarity of
osteosarcomas. A limited number of studies have been performed investigating a
subset of common cancer-related mutations in a small cohort of cell lines and patient
samples. Large scale efforts to more comprehensively identify both epigenetic and
genetic drivers in osteosarcoma are currently being performed, which will allow for the
interrogation of a number of new targets [3]. Thus far, it has been recognized that the
mutational landscape of osteosarcoma is highly heterogeneous, which has made
identifying therapeutic agents quite difficult.
One hallmark that has been recognized in osteosarcomas is chromosomal
instability. This is characterized by a high degree of gains and losses of segments, or
4

even whole chromosomes that may result from a loss of function of DNA damage
response pathways or cell cycle checkpoint pathways [8]. There is no main mutational
driver, fusion gene or translocation event that is associated with the development of
osteosarcoma [1, 3, 8]. It is a cancer that is defined by heterogeneous and widespread
abnormalities in chromosomal number and structure. There are a number of common
sites of chromosomal changes that have been identified which include the most
common deletions in the segments of chromosomes 9, 10, 13, and 17, while the most
common gains are seen in chromosome 1 [8]. Additionally, the most common copy
number alterations include amplifications of chromosomes 1, 6, 8, and 17, while
deletions in portions of chromosomes 3, 6, 9, 10, 13, 17, and 18 are also common [8].
Many of these common sites also encode several tumor suppressor genes as well as
oncogenes [8].
The two most common tumor suppressor genes that have been identified are
TP53 and RB1 [3]. p53 is a transcription factor that regulates crucial genes in cell cycle
progression, apoptosis and the DNA damage response [9]. It has been identified as a
tumor suppressor in an overwhelming number of tumor types and can be altered in a
number of ways including mutations and deletions in the TP53 gene itself, as well as
mutations in either upstream or downstream mediators of its cell signaling activity [9].
TP53 loss of function presents in as much as seventy-five percent of osteosarcoma
cases, which can include point mutations, allelic losses and even chromosomal
rearrangements [8]. RB1 is a critical regulator of the cell cycle, specifically in the G1 to
S cell cycle transition [10]. The loss of function of the Rb pathway occurs in up to
seventy percent of cases of osteosarcoma [8]. The most common Rb alteration is loss
of heterozygosity, but additional modifications also include point mutations and
structural rearrangements [8]. A number of other tumor suppressors that have been
5

identified include APC, BUB3, FGFR2, LSAMP, RECQL4 and WWOX, whose altered
function have been associated with osteosarcoma progression [8].
There are a number of oncogenes that have been identified including E2F3,
CDK4, MDM2, and c-Myc [8]. CDK4 and E2F3 are both involved with the control of cell
cycle progression mediated by the Rb pathway [10]. These genes have been shown to
counteract the control of RB1 [10]. Sixty percent of osteosarcomas are estimated to
possess a gain of function mutations in E2F3 while ten percent of tumors are estimated
to showcase a gain of function mutation in CDK4 [8]. MDM2 is a negative regulator of
the p53 pathway and is amplified in up to twenty-five percent of tumors [8, 9]. C-Myc is
a well-described oncogene in many cancers and can be considered a general amplifier
of genetic expression [11, 12]. It also correlates with cancer progression, metastasis,
resistance, and survival [11, 12]. It has also been shown to be amplified in up to sixtyseven percent of osteosarcoma tumors [8]. There have also been identifications of
common amplifications in other oncogenes which include CDC5L, MAPK7, MET, PIM1,
PMP22, RUNX2 and VEGFA [8].
Collectively, alterations in the Rb and p53 pathways appear to function through
either gains or losses in critical mediators in signaling that results in the loss of cell
cycle control which are exacerbated by an inappropriate DNA damage response [9,
10]. These are understood to be key drivers in the development of osteosarcoma, but
the role that these genetic alterations play in cancer progression and eventual
metastasis have been less clear to this day.
In recent years, there have been a vast number of studies that have identified a
number of epigenetic mechanisms that are drivers of cancer development and
progression. In osteosarcoma, the most well-described mechanisms involve alterations
in DNA methylation, histone modifications, nucleosome remodeling and RNA-mediated
6

events [8]. DNA methylation is an important mechanism of epigenetic silencing [13, 14].
A number of key methylation sites have been identified in both the p53 and Rb
pathways, which result in loss of function [8]. There have been numerous studies that
have identified gene silencing through hyper-methylation of several other tumor
suppressor genes, leading to tumor development and progression [13, 14].
Although as high as seventy-five percent of the human genome is capable of
being transcribed, an incredible one to two percent of genes actually code for proteins
[15-17]. Noncoding RNAs are a key part of many cellular processes and many have
been linked to cancer development, progression and metastasis. Noncoding RNAs are
classified broadly by size [18]. Long noncoding RNA is typically defined as transcripts
whose length exceeds two hundred base pairs, where everything below that threshold
is considered small RNAs [18]. The most well studied of these small RNAs are
miRNAs, which can either inhibit translation or induce degradation by binding to
messenger RNA transcripts [19]. miRNAs act post-transcriptionally to silence a large
number of genes. A number of studies have indicated that the dysregulation of miRNA
expression results in the aberrant expression of key cancer related genes which leads
to tumorigenesis and cancer progression [19]. In osteosarcoma, miRNAs can modulate
a number of cellular signaling pathways that are key to pathogenesis which include
FAS, RAS, WNT, MAPK and Notch [8]. A number of miRNAs have been shown to be
downregulated in osteosarcoma, including miR-16, miR-34, miR-133a, miR-143, miR199a-3p, miR-335, and miR-340 [8]. Several miRNAs have been shown to be elevated
in osteosarcoma which include miR-20a, miR-29a, miR-140, and miR-18 [8]. The
overexpression of miR-20a is correlated with osteosarcoma metastasis and acts to
epigenetically downregulate the expression of FAS, a key mediator in the apoptotic
process [20-24]. More studies are needed to more thoroughly understand the role that
7

epigenetic modifications play in the development, progression and metastasis of
osteosarcoma.
Osteosarcoma displays a tremendous breadth of genetic abnormalities relative
to normal tissues and presents with a large degree of intratumor heterogeneity and it is
likely that the mechanisms of the acquisition of these anomalies represent a broad
spectrum [8]. Classic models of genetic mutation are certainly seen. An example would
be point mutations in DNA replication and proof-reading genes, which would result in a
number of subsequent errors [25-27]. Additionally, aneuploidy would result in errors in
segregation during the process of cell division [25-27]. Recently, another method for
the acquisition of mutations has been identified. Chromothripsis describes an event
where tens to hundreds of genetic rearrangements occur in a single cellular crisis and
occurs by the reciprocal exchange of information within and between chromosomes
[28]. In contrast to the more traditional model of the gradual accumulation of genetic
abnormalities in cancer cells and subsequent clonal selection, chromothripsis points to
a punctuated equilibrium method of tumor evolution [25-28]. Chromothripsis occurs in
only two to three percent of all cancers but occurs in an incredible thirty-three percent
of osteosarcoma [28]. This phenomenon of cancer evolution needs to be better
understood, especially in the context of osteosarcoma.

1.1.4: Primary and Metastatic Osteosarcoma Tumor Microenvironments
Osteosarcoma has a high propensity to metastasize almost exclusively to the
lung [2, 3, 8]. Once this occurs, patient survival rates drop drastically, indicating a clear
clinical need to study the mechanisms of metastasis in addition to better understand
the fundamental systems that may affect an osteosarcoma cell’s ability to grow,
proliferate and continue to survive even in the face of adjuvant chemotherapy or
8

immunotherapy [1-3]. The tumor microenvironment is becoming increasingly
recognized to play a role in cancer initiation, progression and eventual metastasis. A
tumor does not consist of only cancer cells but is composed of stromal cells such as
fibroblasts and myofibroblasts, mesenchymal stem cells, adipose cells, immune and
inflammatory cells, blood and lymphatic vascular networks, as well as extracellular
matrix [29-31].
The primary tumor microenvironment of osteosarcoma is unique in that it
contains osteoclasts and osteoblasts in addition to stromal cells and extracellular matrix
[32]. It is currently understood that various proteins and factors secreted by both cancer
cells and stromal cells can cause the aberrant activation of a multitude of paracrine and
autocrine loops, which can affect the status and progression of a tumor [29-31].
Osteosarcoma cells are capable of acting in an osteoblastic manner by producing
osteoid matrix and are also capable of acting in an osteolytic nature by permeating soft
tissue and cortical bone, which will likely affect the surrounding tumor
microenvironment [8]. Additionally, osteoclast-mediated destruction of bone tissue
results in the release of a wide variety of tumor-promoting factors such as TGFB, which
is usually stored within the bone in its latent form [31]. In addition to the above factors,
the bone microenvironment is unique in that there are resident stem cells and
progenitor cells, which have been shown to attract and support dissemination of tumor
cells [32]. It has also been shown that bone-marrow derived mesenchymal cells
contribute to primary tumor growth and invasion [33, 34]. The tumor microenvironment
in primary osteosarcoma has been shown to be particularly important in cancer
progression.
In contrast, the microenvironment of a metastatic tumor in the lung is more
epithelial in nature and involves the interaction with resident immune populations of the
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lung [35]. While there are no osteoclasts and osteoblasts within the lung, there are a
wide variety of circulating immune cells as well as a number of resident immune
populations including alveolar macrophages, natural killer cells, dendritic cells and T
cells [36]. These lung specific resident immune cell populations are likely to behave
differently than those in the bone or those recruited from the blood, which may play a
role in exacerbating the increasing aggressiveness of metastatic tumors [36]. In
addition to unique immune cell populations, metastatic osteosarcoma cells may
encounter goblet cells, basal cells, club cells as well as other factors specific to the lung
microenvironment (Figure 1) [35]. It is important to study both the primary and
metastatic tumor microenvironments because it might illuminate different therapeutic
targets that may benefit patients with or without metastasis.
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Figure 1: A schematic of the normal lung showing anatomic regions encompassing the
proximal and distal airways is shown. The proximal airways are composed of ciliated
cells, secretory club cells, undifferentiated basal cells, mucus-producing goblet cells
and neuroendocrine cells; the distal airways are composed of alveolar type I and type II
cells. Other cell types in the lung microenvironment include smooth muscle cells,
fibroblasts, endothelial cells and immune cells, including resident alveolar
macrophages and dendritic cells. Vascular capillaries line the alveolar walls to facilitate
gaseous exchange and infiltration of circulating immune cells. Resident alveolar
macrophages maintain immunological homeostasis; however, they can also contribute
to inflammation and the development of pre-malignant lung lesions in mice. A
population of tissue-resident memory T cells resides in the lung airways, and they are
generated by a diverse set of pathogens penetrating mucosal barriers and are believed
to confer protective immunity to secondary infections. ECM, extracellular matrix.

This figure and its corresponding figure legend were taken with permission from Altorki,
N.K., Markowitz, G.J., Gao, D., Port, J.L., Saxena, A., Stiles, B., McGraw, T., Mittal,
V. The lung microenvironment: an important regulator of tumour growth and
metastasis. Nat Rev Cancer 19, 9–31 (2019). https://doi.org/10.1038/s41568-0180081-9
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1.1.5: Summary
In summary, osteosarcoma is a highly heterogeneous cancer that presents with
a tremendous amount of genomic complexity. Standards of care generally include
surgical resection along with neoadjuvant chemotherapy. Despite many recent
advances in the treatment of cancer, the survival rates for patients have remained
stagnant for the past fifty years. More study is needed to further understand
osteosarcoma on a greater scale including broad scale genomic and proteomic studies.
There is also a lack of understanding as to how osteosarcoma develops and
progresses, especially in the context of how the primary and metastatic tumor
microenvironments play a role in tumorigenesis. Exploring the role that the tumor
microenvironment might play in the progression of osteosarcoma might reveal new
therapeutic targets and opportunities that will better improve patient outcome in those
with and without metastatic disease in the lung.

1.2 The Immune Response in Osteosarcoma

1.2.1: Overview of the Innate Immune System
It is well established that cancer cells can adopt various mechanisms in order to
bypass stringent safety checks within the human body, allowing a tumor to grow
uncontrollably and without check [37, 38]. Cancer cells showcase limitless replicative
potential, insensitivity to antigrowth signals, self-sufficiency in growth signals, the
evasion of apoptosis, sustained angiogenesis, and replicative immunity, the activation
of invasion and metastasis, as well as mechanisms to resist stress related to DNA
damage, mitosis, metabolism, oxidative factors and proteotoxic factors [37, 38]. In
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addition, cancer cells have also been shown to evade immune surveillance in a variety
of ways [37]. The immune system functions in recognizing and eliminating the vast
majority of cancer cells and tumors, however cancer cells can adopt various
mechanisms to disable certain components of the immune system resulting in the
eventual evasion of the body’s natural defenses [37]. Some of these mechanisms
include the expression of anti-inflammatory cytokines, the downregulation of key
receptors involved in immune cell killing, interactions with T-regulatory cells and
mesenchymal derived stem cells to induce a more immunosuppressive
microenvironment, as well as overexpression of certain factors such as PD-L1 in order
to avoid immune surveillance [39].
The immune system comprises of two major arms; adaptive immunity and innate
immunity. Adaptive immune cells include B cells and T cells. The innate immune
system includes natural killer cells, neutrophils, dendritic cells, mast cells, basophils,
eosinophils and macrophages [40]. Adaptive immunity is specific to the pathogen that
is encountered while the innate immune system is non-specific [41]. The innate
immune system is first to respond within the first ninety-six hours and is immediately
available for action [41]. The adaptive immune system is correlated with long term
immunity and is responsive after the first ninety-six hours. It is antigen dependent and
involves the clonal expansion of both T and B lymphocytes [41]. The adaptive immune
system response is highly specific, long-lasting and is sustained over a long period of
time by memory T cells [41]. It is well understood that the adaptive immune system
plays an important role in both promoting and suppressing tumor progression, but the
innate immune system is becoming increasingly recognized to play an important role in
the tumor microenvironment as well as cancer development, progression and both the
establishment and progression of metastatic lesions [40]. Recently, macrophages, an
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integral part of the innate immune system, have been shown to play critical roles in the
tumorigenesis of many cancers, including osteosarcoma [42-45].

1.2.2: Macrophage Function
Macrophages have a variety of functions. They provide a first line of defense
against intracellular pathogens and are considered professional phagocytes [41].
Macrophages are highly specialized cells of the innate immune system that function in
the removal of dead or dying cells, microbes, cancer cells, cells not recognized as self
as well as cellular debris, all of which are especially important in cases of chronic
inflammation such as cancer [45]. Macrophages have been shown to play many roles
and are capable of phagocytosis, efferocytosis, macrophage-mediated cell killing,
antigen presentation, uptake of antigens and antibodies as well as the release of
antimicrobial factors such as reactive oxygen species in order to combat infection [46].
They also function in the process of development, wound healing, tissue repair, the
regulation of normal cell turnover, and homeostasis within the human body [47, 48].
Macrophages are derived from circulating monocytes and display tremendous
functional heterogeneity [45]. They are found in every tissue, including the brain and
other immune privileged areas of the body. Resident tissue macrophages play a major
role in regulating homoeostasis and act as sentinels that respond to physiological
changes as well as outside challenges [45]. Additionally, macrophages with differential
phenotypes can be recruited from the blood, spleen, and the bone marrow, as well as
local cellular proliferation and resident tissue progenitors [45, 47, 48]. Tissue
macrophages and recruited macrophages often showcase differences in phenotype
and function depending on the context of the surrounding microenvironment [45, 47,
48]. In the bone, macrophages and osteoclasts function to remodel the bone and are
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an important part of hematopoiesis [32]. In the lung, macrophages play a crucial role in
maintaining tissue homeostasis even in the face of constant exposure to microbes, dust
and pollutants [36]. Therefore, one of the main roles of alveolar macrophages is to
tolerate innocuous stimuli while also preserving the capability of mounting an
inflammatory immune response against more opportunistic pathogens [49].

1.2.3: The Role of Macrophage Phenotype in the Tumor Microenvironment
Macrophages have a wide range of phenotypic plasticity depending on a variety
of factors that include signaling in the surrounding microenvironment as well as
interactions with nearby cells [50-53]. There are two classical accepted phenotypic
groups that are broadly deemed M1 or M2 macrophages [54]. It should be noted that
the polarization of a macrophage is a complex phenomenon that is not completely
understand and that M1 and M2 classifications are a somewhat simplistic system [53].
Macrophages have been shown to be extremely plastic in nature depending on
surrounding stimuli and it should be recognized that both M1 and M2 macrophages
represent rather extreme ends of the spectrum [52].
M1 macrophages are considered classically activated macrophages and
function in the promotion of inflammation, tissue injury and the stimulation of the
immune system [54]. They are associated with TH1 programming which involves the
secretion of inflammatory cytokines and chemokines such as IL1B, TNFa, CXCL2,
CXCL9 and CXCL10 [50, 52]. In the context of the tumor microenvironment, M1
macrophages are considered to be tumor-suppressing and have been correlated with
extended patient survival as well as improved patient outcome [50, 52]. M1
macrophages are typically activated by TNF-alpha, M-CSF, IFN-gamma or bacterial
lipopolysaccharide (LPS) [54]. M1 macrophages also show a high capacity for antigen
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presentation and secrete reactive oxygen species [54]. M1 macrophages also typically
rely on the anaerobic glycolytic pathway, which functions to meet rapid energy
requirements that are needed to quickly trigger activity against microbes or pathogenic
stimuli [54].
In contrast, M2 macrophages are anti-inflammatory and are typically immune
regulatory [54]. M2 macrophages play a role in matrix deposition, scavenging, as well
as tissue repair and remodeling [50, 54]. M2 macrophages are associated with
TH2/TH17 programming, which involves the secretion of anti-inflammatory cytokines
and chemokines such as IL10, TGFB, CXCL17, CXCL18, and CXCL22 [54].
Additionally, M2 macrophages are commonly referred to as tumor associated
macrophages (TAMs) and have been shown to promote tumorigenesis [54]. M1 and
M2 macrophages also differ metabolically in that M1 macrophages have the unique
ability to metabolize arginine to nitric oxide which is associated with cell killing while M2
macrophages metabolize arginine to ornithine which is associated with cellular repair
[54]. M2 macrophages can be activated by a wide range of signals such as IL10, IL13,
IL4, TGFB, and VEGF [50-54]. M2 macrophages also typically require sustained
energy and are believed to rely on oxidative glucose metabolism in order to carry out
regulatory functions within the surrounding microenvironment [54].
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Figure 2: A schematic of the phenotypic spectrum of M1 and M2 macrophages.

This figure was taken with permission from Nadella V, Singh S, Prakash H (2016)
Macrophages directed approaches are paramount for effective cancer
immunotherapies. Integr Cancer Sci Therap. 3: DOI: 10.15761/ICST.1000189.
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M1 and M2 macrophages have been shown to play remarkably different roles in
the tumor microenvironment. Broadly, M1 macrophages suppress tumor growth while
M2 macrophages promote the progression of a tumor [50]. Cancer cells have been
shown to release many factors that have been linked to the promotion and polarization
of M2 macrophages which ultimately dampen the immune response and allows for the
tumor to evade immune destruction [55]. In many human tumors, a high infiltration of
tumor associated macrophages is correlated with poor prognosis in cancers such as
lung cancer, pancreatic cancer, breast cancer, gastric cancer, and esophageal cancer
[56-60]. Additionally, a high number of TAMs have been observed in advanced tumor
stages including pancreatic cancer, breast cancer, ovarian cancer, and esophageal
cancer [60-63]. There is some disparity in these studies as some investigations indicate
that the density of tumor associated macrophages has a negative impact on patient
prognosis, while others oppose it [64-70]. These studies mostly involve the total
number of macrophages rather than evaluating M1 and M2 macrophages separately.
Recently, it has been shown the M1/M2 ratio is more biologically relevant as a
prognostic indicator as compared to whole TAM densities and could represent either a
negative or positive impact on tumor growth and patient survival [71, 72].
In many cancers, TAMs generally express an M2-like phenotype [50, 52, 54, 55].
Macrophage content comprises up to 50% of its total mass within solid tumors, thereby
making TAMs the predominant infiltrating leukocyte [73]. They present with high IL-10
expression, low tumoricidal activity and promote angiogenesis, tissue remodeling and
tumor-cell proliferation [50, 52, 53, 55]. Additionally, the production of IL-10, TGFB2
and PGE2 by TAMs as well as cancer cells all contribute to the general suppression of
antitumor activities [74]. IL-10 is an extremely potent cytokine that promotes the
differentiation of monocytes to macrophages, while also blocking their differentiation
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into dendritic cells [75-77]. This is supported by the infiltration of TAMs in a tumor such
as papillary carcinoma where dendritic cells are only present along the periphery [50,
52, 54]. In addition, IL10 promotes the differentiation of macrophages to the M2
subtype and promotes a number of tumor supportive activities [50, 52, 54].
Furthermore, TAMs have also been shown to be poor producers of nitric oxide [78]. In
ovarian cancer, only a small number of macrophages on the periphery of the tumor
scored positive for iNOS [79]. Lastly, TAMs have been shown to be poor producers of
reactive oxygen species, further supporting their role as M2-like macrophages [79].
TAMs have been shown to express low levels of inflammatory cytokines such as
IL1B, TNFa, and IL12 [74]. In order to promote transcription of these inflammatory
cytokines, the activation of NFKB signaling is necessary and TAMs are defective in this
signaling in response to M1-promoting stimuli [80]. Further supporting the M2-like
signature, TAMs express high levels of the mannose receptor as well as scavenger
receptor-A [54]. Additionally, TAMs have been shown to be poor antigen presenting
cells [54]. TAMs have been shown to influence nearly every step during the process of
carcinogenesis and the progression of a tumor [54]. They have been shown to promote
and contribute to genetic instability and alterations, regulate senescence, promote both
lymphogenesis and angiogenesis, promote invasion and metastasis, interact and
remodel the surrounding extracellular matrix, as well as suppress multiple cells of the
adaptive immune system [50, 52-55].
Angiogenesis is considered to be a crucial part in the progression and growth of
a tumor [37, 38]. TAMs have been shown to be associated with angiogenesis, and in
many cancers, produce factors such as VEGF and plate-derived endothelial growth
factor, both of which play key roles in angiogenesis [74]. Macrophages also produce
IL8, VEGFA, VEGFC, and EGF, which support the promotion of lymphogenesis as well
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as angiogenesis [74, 81-83]. In cervical cancer, the production of VEGFC by TAMs
specifically was correlated with lymphogenesis as well as the subsequent
dissemination of cancer cells that development into lymphoid metastases [84].
Additionally, macrophages can act as a sort of “cellular chaperone” or “bridge cell” that
guide the fusion of endothelial tip cells and facilitate vascular sprouting, which is
important to the process of angiogenesis [81]. Furthermore, TAMs contribute to the proangiogenic environment by producing chemokines such as CCL2 [85]. Lastly, TAMs
also have been shown to accumulate in hypoxic tumor regions and contribute to trigger
an angiogenic programming in the surrounding cells [54].
TAMs express factors that also affect tumor cell growth and proliferation as well
as tissue remodeling [50, 54]. TAMs have been shown to release TGFB as well as
PDGF, which contributes to the formation of stroma and angiogenesis in lung cancer
[74]. Macrophages in the tumor microenvironment have also been shown to release
enzymes and inhibitors that digest the surrounding extracellular matrix, such as MMP9,
plasmin and urokinase-type plasminogen activator (uPa) and its cognate receptor [86,
87]. MMP9 has been directly correlated with carcinogenesis in skin cancer and has
also been suggested to play a role in the angiogenic switch as well as the release of
tumor-promoting growth factors [87]. In breast cancer, macrophages have been found
to be present in areas that showcase basement membrane breakdown and invasion
and were shown to express upregulated levels of proteolytic enzymes such as
cathepsin B [88]. Co-culturing tumor cells and macrophages together increases the
invasive properties of the tumor cells through MMPs and TNFa [89]. TAM infiltration
has been positively correlated with tumor growth in renal cell carcinoma, breast cancer
and endometrial cancer [90-92]. Finally, the secretion of factors such as TGFB, EGF,
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FGF and HGF by TAMs have been linked to cancer cell proliferation and increased
tumor growth [93].
Recent studies have also suggested that TAMs play an important role in both
the establishment and progression of metastasis [50]. In many cancers, a higher
number of macrophages found within a primary tumor have been correlated with the
early establishment of metastasis [94, 95]. In vivo imaging has revealed that
macrophages are almost always in juxtaposition with cancer cells that have moved
away from the main tumor as well as the discovery that extravasation of tumor cells into
the surrounding blood vessel typically occurs at clusters of macrophages attached to
the vessels [96, 97]. Inhibiting EGF or CSF1 signaling will inhibit both of these
processes [96, 97]. In breast cancer models, the depletion of macrophages has
resulted in the reduced formation of lung metastases [88]. It has been shown that
alveolar macrophages release MMP9, which is important to a tumor cells ability to
colonize and grow within the lung [98]. Finally, clinical studies have also suggested that
increased numbers of macrophages within lymphoid metastases correlate with poor
patient outcome and survival [99].
TAMs have also been shown to elicit immunosuppressive effect on both innate
and adaptive immune cells within the tumor microenvironment [50, 54]. The
downregulation of macrophage expression of IL12 within the tumor inhibits the
proliferation and cytotoxicity of NK cells [80, 100]. TAMs have been shown to suppress
both the activation and proliferation of T cells [74]. For example, TAMs have been
shown to secrete CCL18, which will induce T cell anergy [101]. Furthermore, TAMs
also secrete CCL2, CCL17 and CCL22, which function to act on T-helper cells and
inhibit Th1 effectors [54]. Additionally, the release of IL10 and TGFB by TAMs have
been linked to the activation of T-regulatory cells which function to suppress many
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aspects of the immune system [102]. Finally, the release of IL10, TGFB, VEGF and IL6
have been shown to inhibit the maturation and activation of tumor associated dendritic
cells, which are subsequently ineffective in mounting an anti-tumor response [54].
Lastly, TAMs have been shown to release MMP7, which functions to cleave FAS ligand
from neighboring cells, thereby making lysis of cancer cells by NK and T cells less
likely to occur [103, 104]. The immunosuppressive effects of TAMs are still being
extensively studied and elucidated today.

1.2.4: The Role of Macrophages in Osteosarcoma
In osteosarcoma, the innate immune system is becomingly increasingly
recognized to play a role in tumor progression and patient outcome [43, 44]. The role
that macrophages play in osteosarcoma is still not well understood and highly
controversial [105]. Similar to other cancers, M1-like macrophages have been shown to
inhibit tumor growth in osteosarcoma [105]. A higher density of TAMs correlates with
better patient outcome [106]. In that same study, the TAMs exhibit markers of both M1like and M2-like macrophages [106]. In contrast, it has also been suggested that the
switch from M1 to M2 macrophages may support osteosarcoma metastasis [50]. In
agreement with another study, macrophages switch from M1 to M2 within the first two
to three weeks of formation in a mouse model of osteosarcoma [107]. Osteosarcoma
cells themselves have been shown to secrete IL-34, which increases the recruitment of
M2 macrophages into the tumor [108]. In osteosarcoma patients, M1 and M2
macrophages were found to be contained within the tumor and the total number of
macrophages was associated with better patient survival, however the M2 phenotype
was correlated with poor prognosis [109]. Additionally, it has been shown that a
dysregulation of the balance between M1 and M2 TAMs in favor of M1 occurred in non23

metastatic patients [105]. In preclinical models of osteosarcoma, M2 macrophages
have been correlated with increased tumor growth, increased vascularization and
increased metastatic dissemination [110]. In an implanted osteosarcoma tumor model,
it was shown that TAMs were polarized to the M2 subtype and that depletion of those
TAMs resulted in decreased tumor growth, further supporting the role of M2
macrophages in the progression of osteosarcoma [107].
Many of these studies have looked at the macrophage content within a primary
tumor though, and it should be noted that the contribution of macrophages may differ in
primary versus metastatic osteosarcoma tissues, especially when the consideration of
different tumor microenvironments is taken into account [105, 106, 108]. The bone
microenvironment and the metastatic niche within the lung are two very different
tissues with very different physiological roles and it is possible that the role of a
macrophage may differ depending on the location of the tumor. It also unclear whether
the metastatic status of the osteosarcoma cell contributes to the modulation of
macrophage phenotype and function. Further investigation is needed to fully elucidate
the role that macrophages play in both non-metastatic and metastatic osteosarcoma
microenvironments.
The repolarization of M2 macrophages into the M1 subtype has recently shown
promise as a novel therapeutic strategy in cancer patients [43, 44]. In non-small cell
lung cancer, an increase in M1 macrophages with a concurrent decrease in M2
macrophages was associated with increased survival in patients [111]. This strategy
has also shown promise in the treatment of osteosarcoma. Liposome-encapsulated
muramyl tripeptide (L-MTP-PE) is a synthetic analog derived from components of the
bacterial cell wall, which when combined with IFNg, acts to activate macrophages to
the M1 phenotype by the release of soluble mediators [112]. The use of L-MTP-PE in
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osteosarcoma patients had a beneficial impact on survival [113-115]. Furthermore, antiPD-1 therapy redirects M2 macrophages to the M1 phenotype and ultimately resulted
in the regression of osteosarcoma lung metastases [116]. Additional therapies targeting
M2 macrophages in osteosarcoma include the use of all-trans-retinoic acid, as well as
dihydroxycoumarins, which acts to inhibit the differentiation of macrophages into the
M2 subtype [117, 118]. Thus, it may be possible to increase the M1/M2 ratio and
prevent the repolarization of M1 to M2 macrophages, which might prove beneficial in
patients with and without osteosarcoma metastasis.

1.2.5. Summary
In summary, the innate immune system plays an important role in the
development of cancer, as well as its subsequent progression and metastasis. TAMs
are commonly associated with the M2 subtype, which have been linked to increased
tumor progression and generalized immune suppression. In the context of
osteosarcoma, macrophages are becoming increasingly recognized to be important to
patient survival and outcome. Macrophages plays an integral role in this process,
resulting in differing outcomes depending on the phenotypic context of this crucial
phagocyte. Additionally, it is not clear what the role of a macrophage may be in a
primary osteosarcoma tumor versus a metastatic tumor in the lung. More studies are
needed to better understand the roles that macrophages play within osteosarcoma, as
well as how cellular communication between a cancer cell and a macrophage may
contribute to the further progression of the tumor.

1.3 Chapter Summary

25

Osteosarcoma is a highly heterogeneous tumor within the pediatric population. It
is a cancer with highly complex genomics that requires a deeper understanding of its
basic biology, including the differing tumor microenvironments of both the primary and
metastatic tumors. It should be noted that the bone and lung microenvironments are
very different tissues with very different physiological roles within the human body. As
such, cells within either a primary or metastatic tumor may interact with others in
differing ways. It is also becoming increasingly recognized that cellular communication
between a cancer cell and the surrounding tumor microenvironment is important to its
further growth and progression. The innate immune system has gained significant
interest in recent years and had been shown to be important to osteosarcoma
tumorigenesis, which includes macrophages and their role within a tumor. These critical
phagocytes are being increasingly recognized to play many crucial roles in
tumorigenesis and further study of these cells within a tumor are warranted. The next
chapter will focus on a mechanism of extracellular communication that has received
significant interest in recent years to play an important role in both cancer progression
and metastasis.
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CHAPTER TWO: THE ROLE OF EXOSOMES IN THE TUMOR
MICROENVIRONMENT

This work is based upon “Exosomes: Dynamic Mediators of Extracellular Communication
in the Tumor Microenvironment” by Wolf-Dennen, K, Kleinerman, E, C. 2020. Springer;
presented with permission from Springer.

2.1: Introduction
Cell to cell communication within complex tissue microenvironments such as
cancer is crucial to the sustained growth, invasion and metastasis of cancer cells [37].
It is also becoming increasingly recognized that the tumor microenvironment is
dynamic, heterogeneous and composed of a wide variety of cells including tumor cells,
innate and adaptive immune cells, fibroblasts, pericytes, endothelial cells and
mesenchymal stem cells [37, 119]. The tumor microenvironment is also comprised of
extracellular matrix, collagen, fibrotic tissue, necrotic tissues, areas of hypoxia and a
diverse array of growth factors. Communication within the tumor microenvironment is
complex as it can occur either intercellularly or extracellularly, which can be mediated
by direct contact between cells or by the transfer of secreted molecules or extracellular
vesicles such as exosomes [120-122].
Exosomes are very small, 30-to 150-nm vesicles that have been shown to be an
integral part of intercellular communication [121]. Furthermore, they have been shown
to be released by a wide variety of cells, including both normal cells and cancer cells in
vitro and in vivo [121]. Exosomes can also be found in many body fluids, including
blood, urine, semen, breast milk, saliva, amniotic fluid as well as ascites fluid [123].
Exosomes arise at the lipid raft domain of the plasma membrane, where endocytosis
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leads to the intracellular formation of an early endosome. These endosomes undergo a
maturation process and become late endosomes, which then invaginate and give rise
to multi-vesicular bodies. Then, these multi-vesicular bodies are either degraded within
lysosomes or are released into the extracellular space as exosomes [121, 124]. In
addition, exosomes have also been shown to be secreted by pathogens such as fungi,
archaea, mycobacteria, and bacteria, as well as plant and animal cells, which suggests
that the biogenesis and subsequent exosomal communication between cells is an
important evolutionary conserved signaling mechanism [123].
Exosomes have been shown to contain a wide variety of constituents, such as
proteins, mRNAs, miRNAs, as well as both single-stranded and double-stranded DNA
[125]. In addition, the generation of exosomes by inward budding ensure that the
membrane proteins on the surface of an exosome preserve the same orientation and
folding as those on the plasma membrane [124]. Exosomes have been shown to be a
rich source of biomarkers and have also been shown to play a role in a wide variety of
normal physiological processes such as tissue regeneration, angiogenesis, autophagy,
blood coagulation, immunomodulation, stem cell differentiation, wound healing,
pregnancy, as well as cancer progression [123, 125-128]. Exosomes have also been
proposed to mediate cellular communication during the normal development of the
nervous system and regeneration of normal neurons [125, 127]. Importantly, the
discovery that the contents of an exosome can be transferred to a recipient cells and
can mediate both cellular signaling and phenotypic changes within cells supports the
idea that exosomes are dynamic mediators of intercellular communication, both locally
and distantly [123].

2.2: The Role of Exosomes in Cancer
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Exosomes have been detected within the tumor microenvironment, and
emerging evidence suggests that exosomes play a role in regulating tumor
proliferation, survival, angiogenesis, resistance, migration, invasion, lymphogenesis,
cancer development, progression and metastasis [126]. An increase in the rate of
exosome secretion as well as differential cargo expression has been shown to be
favorable in the development of cancer [129]. Within the tumor microenvironment,
exosomes can mediate interactions between cancer cell to cancer cell, cancer cell to
stromal cell, or stromal cell to cancer cell. For example, exosomes derived from a
glioblastoma-astrocytoma cell line containing mutant EGFR variant III (EGFRvIII)
expression can transform glioblastoma cells lacking EGFRvIII expression [130]. Breast
cancer derived exosomes can also transform non-malignant mouse fibroblast cells,
which will form tumors [131]. Exosomes can also transfer oncogenic proteins or fusion
gene mRNA, as well as oncogenic lncRNAs from cancer cells to other cells within the
tumor microenvironment [123]. In addition, non-malignant breast cells form tumors
when exposed to exosomes from breast cancer cells or exosomes isolated from the
serum of breast cancer patients [132]. Exosomes play many roles in the tumor
microenvironment and it is becoming increasingly recognized that they may play a
much bigger role in tumor growth and metastasis than originally thought.

2.2.1: The Role of Exosomes in Drug Resistance
The ability of cancer cells to adapt and become resistant to radiotherapy,
chemotherapy or even immunotherapy is an unsolved problem to date. It is becoming
increasingly understood that exosomes may contribute to resistance, specifically
because of their ability to confer the resistant phenotype to non-resistant cancer cells in
the tumor microenvironment using several different mechanisms [133]. Exosomes have
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been shown to package chemotherapeutic agents such as cisplatin from the cytosol
which acts to protect the surrounding cells from the cytotoxic effects of the drug [134].
Additionally, exosomes have also been shown to mediate resistance from a drug
resistant cell to a drug sensitive cell simply by the transferal of exosomal contents
[133]. For example, adriamycin and docetaxel resistant breast cancer cells transferred
miRNAs mediating resistance via exosomes to sensitive cell lines, resulting in the
conference of resistance to both drugs [135]. Additionally, breast cancer cell exosomes
have been found to carry HER2 and have also been shown to scavenge trastuzumab,
thereby reducing its availability in circulation [136, 137]. In prostate cancer, exosomes
have been shown to both carry and induce production of multi-drug resistance protein
(MDR-1/P-gp), which interferes with drug uptake, increasing cellular resistance to drugs
such as docetaxel and anthracyclines [138]. Many studies have identified the exosomal
transfer of miRNAs that mediate drug resistance, but more comprehensive genetic and
proteomic investigations are needed to better understand the complex mechanisms
responsible for exosome-mediated induction of resistance, how this is transferred
between sensitive and resistant cells and which signaling pathways are involved.

2.2.2: The Role of Exosomes in Angiogenesis and Lymphogenesis
Exosomes have also been shown to modulate the tumor microenvironment,
which includes their ability to stimulate angiogenesis and lymphogenesis. Cancer cellderived exosomes can carry TSPAN8 and integrin subunit a4 and have been shown to
upregulate angiogenesis related genes [139]. Additionally, exosomes have also been
shown to carry soluble E-cadherin, which is a potent inducer of angiogenesis and were
also shown to activate b-catenin and NF-kb signaling [140]. It has been suggested that
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tumor-derived exosomes containing EGFR can activate endothelial cells to produce
VEGF and upregulate VEGFR2 signaling [141]. Cancer cell-derived exosomes have
also been shown to carry NOTCH ligand Delta-like 4 (DLL4), which resulted in
increased vessel density and branching in vivo [142]. Within a hypoxic tumor
microenvironment, exosomes have been shown to be especially important in the
promotion of angiogenesis. For example, under hypoxic conditions, lung cancer cells
produced more exosomes enriched in mir-23a, which resulted in accumulation of
hypoxia-inducible factor-1-alpha (HIF1A) in endothelial cells and also targeted tight
junction protein ZO1, thereby increasing vascular permeability [143]. Exosomes have
also been shown to modulate the lymphatic system. As an example, exosomes
released from melanoma cells have been shown to prepare the sentinel lymph node for
tumor metastasis [144]. An exosome’s ability to influence endothelial cells, modify both
local and distant microenvironments and promote angiogenesis can facilitate cancer
progression and metastasis.

2.2.3: The Role of Exosomes in Cancer Cell Proliferation and Survival
Exosomes have also been shown to contain factors that modulate cancer cell
proliferation and survival within the tumor microenvironment. Exosomes derived from
chronic myeloid leukemia cells have been shown to contain the cytokine TGFb-1, which
promoted tumor growth through the activation of anti-apoptotic pathways, as well as
ERK and AKT [145]. Exosomes from cancer associated fibroblasts have been shown to
carry a signal recognition particle RNA that stimulated DDX58 signaling in breast
cancer cells, which lead to increased chemoresistance as well as increased
proliferation [146]. Gastric cancer derived exosomes have been shown to increase
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proliferation in part due to PI3K/AKT activation [147]. In bladder cancer, exosomes
have been suggested to activate AKT and ERK, thereby promoting proliferation and
inhibiting apoptosis in recipient bladder cancer cells [148]. Colon cancer-derived
exosomes containing mutant KRASG12D were shown to induce anchorage-independent
growth in colon cancer cells expressing the wild type KRAS allele [149]. Exosomes
have been associated with increased proliferation and decreased apoptosis in many
cancer types, including but not limited to hepatocellular carcinoma, breast cancer, lung
cancer and osteosarcoma [123, 126, 128, 129]. Additionally, exosomes have also been
associated with replicative immortality, a phenomenon that is associated with
telomerase activation [150]. With each cell replication, cell telomeres are shortened
until the cell reaches a non-dividing stage or replicative senescence. Telomere length is
controlled by the enzyme telomerase [150]. High expression of telomerase is often
associated with cancer [150]. TERT, the catalytic subunit of telomerase, has been
found to be contained within serum derived exosomes from cancer patients [151].
Additionally, TERT mRNA (hTERT) has been found in cancer cell derived exosomes,
including pancreatic cancer and lung cancer [152]. When cancer cell derived exosomes
were added to fibroblasts, these contents were taken up and telomerase was activated,
proliferation was increased and cellular senescence was delayed, thereby extending
the cell’s lifespan [152]. These findings demonstrate that exosomes play a significant
role in cancer cell proliferation and survival. Future studies must now focus on
understanding the mechanisms by which cancer exosomes affect these functional
changes.

2.2.4: The Role of Exosomes in Cancer Migration, Invasion and Metastasis
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Exosomes have also been shown to play a significant role in cancer cell
migration, invasion and metastasis. Exosomes can also control cell polarity and
directional cell movement [128]. Fibrosarcoma cell secreted exosomes that bound to
cell surface integrin receptors facilitated the clustering of integrins, as well as the
formation of a strong adhesion at the leading edge of the cell that promoted cellular
migration [153]. Cancer associated exosomes specifically loaded with WNT1 promoted
the protrusion of breast cancer cells, as well as invasion and metastasis via autocrine
activation of the WNT-planar cell polarity signaling pathway [154]. Exosomes have also
been shown to modify the extracellular matrix (ECM) of the tumor microenvironment.
Metastatic breast cancer derived exosomes contained activated MMP2, which is a
protease that degrades ECM and promotes invasion [155]. Additionally, exosomes
have also been shown to unlock tight junctions of endothelial cells in breast cancer,
which allows for extravasation into the surrounding vasculature and the promotion of
metastasis [156]. Breast cancer-derived exosomes containing miR-181c were shown to
compromise the blood-brain barrier by downregulating PDPK1 in endothelial cells,
which resulted in the abnormal localization of actin and increasing metastasis to the
brain [157]. Exosomes have also been shown to promote the development of a
recipient cell’s epithelial-mesenchymal transition (EMT) [133]. Factors associated with
EMT such as TGFb-1, b-catenin and matrix metalloproteinases have been found to be
contained within cancer cell exosomes [158-161]. In the exosomes of a highly
metastatic lung cancer cell line, levels of vimentin were higher and conferred increased
levels of migration, invasion and proliferation when compared to the exosomes of its
parental counterpart [162]. In another study, cancer derived exosomes contained mir21, which markedly increased the levels of vimentin and snail as well as decreased
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levels of E-cadherin, which are all markers associated with EMT [163, 164]. It is known
that primary tumors release specific growth factors or cytokines, which promotes the
development of metastasis. It has also been recently shown that exosomes can play a
role in the development of the pre-metastatic niche. Cancer cell exosomes can
condition lymph nodes or lungs tissues to become favorable to the metastatic
colonization and subsequent outgrowth of melanoma cells [144, 165]. In prostate
cancer, exosomes promoted osteoblast activity which regulated the microenvironment
of bone metastases [166, 167]. Additionally, exosomes from pancreatic cancer cells
were shown to contain miR-494 and miR-542-3p, which resulted in the downregulation
of cadherin-17 which then increased levels of proteases, adhesion molecules and other
proteins in the lung and lymph node which modulated the local microenvironment and
made it more amenable to tumor metastasis [165]. Melanoma-derived exosomes have
been shown to deliver the tyrosine kinase receptor MET to bone marrow progenitor
cells, which in turn activates HGF-MET signaling, which subsequently promotes tumor
metastasis to the bone [168]. The development of the metastatic niche has been
observed in many cancers, such as pancreatic cancer, breast cancer, melanoma, lung
cancer and gastric cancer [128].

2.2.5: The Role of Exosomes in Cancer and Immune Cell Interactions
In recent years, it has been increasingly clear that cancer cell exosomes play a
major role in the modulation of immune cell signaling and function within the tumor
microenvironment. The first evidence that suggested that exosomes could modulate
the immune system was the discovery that exosomes derived from B-cells that were
transformed by Epstein Bar virus contain MHCI and MHCII on their surface. It was later
found that these exosomes were capable of antigen presentation and can activate
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CD4+ T cells which showed that they can modulate immune cell function independently
of direct cell to cell contact [169, 170]. Since that first discovery, exosomes have been
shown to modulate multiple different types of immune cells, activate or suppress an
immune-mediated tumor response, assist in tumor escape from immune surveillance
and activate various immunosuppressive pathways that support the continual growth of
the tumor [171].
Exosomes have been shown to modulate innate immune cells that may be found
in the tumor microenvironment which include dendritic cells, natural killer cells,
neutrophils, monocytes and macrophages [171]. Additionally, they’ve also been shown
to modulate the adaptive cells of the immune system, T cell and B cells [171].
Exosomes from tumors have been shown to transfer HSP70-80 as well as MHCI to
dendritic cells, which in turn stimulates potent CD8+ anti-tumor effects [172, 173].
HSP70 on the exosomal surface stimulates natural killer cell migration and cytolytic
activity, induce a stronger T helper cell response, and activate macrophages [174-176].
Although exosomes are capable of activating an anti-tumor response, they also have a
very strong pro-tumor effect. Tumor-derived exosomes have been shown to promote Tregulatory cells and have also been shown to inhibit both natural killer and T cell
functions [171]. FAS ligand is a potent activator of cellular apoptosis and can be
presented by tumor derived exosomes, resulting in the apoptosis of activated T cells
[177-179]. Melanoma cell exosomes stimulate high levels of reactive oxygen species
which in turn inhibits the activity of surrounding T cells [180]. Tumor derived exosomes
have also been shown to express PDL1 which supports tumor growth by inhibiting the
activity of activated T cell function [181]. Pancreatic cancer exosomes have been
shown to inhibit dendritic cell activity by downregulating TLR4 via miR-203 [182].
Exosomes derived from breast cancer cells were shown to be taken up by bone
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marrow myeloid progenitor cells, which impaired dendritic cell differentiation by the
phosphorylation of STAT3 and the overexpression of IL6 [183]. Lung cancer exosomes
have been shown to block the differentiation of dendritic cells by downregulating the
expression of MHCII, CD86, and CD80 while also upregulating the expression of PD-L1
and CD11B [184]. Tumor derived exosomes have also been shown to make adenosine
from ATP by carrying the enzymatically active CD39 and CD73 and have been
implicated in the suppression of activated B cells [185].
Tumor cell exosomes have been shown to modulate macrophage polarization.
M1 macrophages are associated with anti-tumor functions as well as the stimulation of
the local immune environment [52]. M2 macrophages are typically immunosuppressive
and have been shown to be tumor promoting. Tumor cell exosomes have been shown
to modulate this phenotype, resulting in an M2-like immunosuppressive phenotype [52].
Exosomes derived from glioblastoma stem cells not only induced an M2 phenotype, but
also induced expression of PD-L1 on macrophages [186]. Breast cancer derived
exosomes were able to modify macrophage polarization through gp130/STAT3
signaling [187]. Exosomes shed from colon cancer cells were shown to contain miR1246 which induced the M2 macrophage phenotype with high levels of TGFb
expression [188]. Gastric cancer exosomes induced the expression of PD-L1 on the
surface of macrophages, and impaired CD8+ T cell function via IL10 secretion [189].
Melanoma, breast cancer and oral squamous cell carcinoma derived exosomes have
been shown to activate macrophages to an M1 phenotype, but also facilitated the
migration of cancer cells, metastasis and immune escape, thus still playing a role in the
progression of the tumor [190-192]. The role of exosomes in the tumor
microenvironment can therefore be both tumor suppressive and tumor promoting. It will
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be important to investigate the mechanisms involved in this complex modification of
cellular signaling, especially in the context of improving the efficiency of immunotherapy
in cancer patients.

2.3: The Emerging Role of Exosomes in Osteosarcoma
The role of exosomes in osteosarcoma is still being elucidated and is not yet
well understood. The first exosomes to be reported in the context of osteosarcoma
found that extracellular vesicle bound uPA contributed to the progression of nonmetastatic osteosarcoma to a metastatic phenotype [193]. In a subsequent study, it
was shown that human osteosarcoma cell exosomes can transfer resistance to
doxorubicin by a mechanism involving the upregulation of MDR-1 and P-glycoprotein
[194]. Proteomic analysis of osteosarcoma cell line derived exosomes has suggested
contents associated with tumor growth and metastasis [195]. Notch-activating factors
have been observed inside osteosarcoma-derived exosomes and have been shown to
mediate skeletal muscle atrophy in cancer cachexia [196]. Osteosarcoma cell-derived
exosomes have also been shown to reduce the rate of T cell proliferation and activity,
as well as promote a T regulatory phenotype [197]. Additionally, exosomes derived
from bone marrow mesenchymal stem cells promoted cancer progression and tumor
growth of human osteosarcoma cells, and increased proliferation, migration, invasion
and apoptotic resistance of osteosarcoma cells [198-201]. Metastatic osteosarcoma
cell derived exosomes have also been shown to contain miR-675 which promotes cell
invasion and migration through CALN1 [202]. miR-1228 has also been shown to be
contained in osteosarcoma derived exosomes which increased cell migration and
invasion through SCA1 [203]. Extracellular vesicle bound miR-25-3p promotes the
capillary formation and invasion of vascular endothelial cells, thereby mediating
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angiogenesis and promoting tumor progression [204]. Osteosarcoma cell derived
exosomes have also been shown to promote osteoclast differentiation, bone resorption
activity, tube formation of endothelial cells and increase angiogenic markers [205].
Osteosarcoma-derived extracellular vesicles have been shown to induce a tumor-like
phenotype in normal recipient fibroblasts [206]. Additionally, osteosarcoma exosomes
that express a membrane associated form of TGFb have been shown to educate
mesenchymal stem cells to an inflammatory phenotype, which then leads to
osteosarcoma progression [201]. Finally, extracellular vesicles secreted by highly
metastatic clonal variants of osteosarcoma preferentially localize to the lungs. These
vesicles are capable of inducing a metastatic phenotype in poorly metastatic clones
[207]. The role of exosomes in osteosarcoma growth and metastasis, how exosomes
from metastatic cells differ from the ones produced by non-metastatic cells and how
metastatic-derived exosomes alter the organ microenvironment specifically in the lung
to make it supportive of tumor growth needs to be elucidated.

2.4: Chapter Summary
The tumor microenvironment is a complex ecosystem composed of many
different cells and components. The organ microenvironment for the primary tumor in
the bone is not the same as the metastatic site, i.e. the lungs. Exosomes play a key
role in extracellular communication between cells. Therefore, future studies need to
include a focus on exosomes from metastatic osteosarcoma cells and the role that
exosomes play in the process of primary tumor development, progression and
metastasis and how exosomes modify the organ microenvironment to make it support
growth at the distant site. A broader understanding of the role that exosomes play in
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extracellular communication of cancer cells and the surrounding tumor
microenvironment may reveal novel therapeutic targets and opportunities and improve
the efficiency of current therapies.

2.5: Aim of Study
Osteosarcoma is the most common primary malignancy of bone in both children
and young adults. Metastasis occurs almost exclusively to the lung and survival rates
drop drastically to below 30% once this occurs. The success of current chemotherapies
has plateaued, showcasing an increasing clinical need to understand this disease.
Characterizing and understanding the biological properties that both permit and support
osteosarcoma cells to grow and thrive in the lung microenvironment may allow for the
development of new therapeutic opportunities in the treatment of metastatic
osteosarcoma. The tumor microenvironment is a complex structure comprised of
surrounding stromal cells, innate and adaptive immune cells, cancer cells, and
mesenchymal stem cells. Recently, macrophages, an integral phagocyte of the innate
immune system, have been shown to be important to patient survival in osteosarcoma
and other cancers. There are two classically accepted macrophage phenotypes: an
anti-tumorigenic M1 phenotype, and a tumor promoting M2 phenotype. Growing
evidence has suggested that a high density of M2-like tumor associated macrophages
is associated with poor prognosis and poor patient survival in many cancers. In both
primary and metastatic osteosarcoma, macrophages recruited to the tumor are
commonly polarized to the M2-like subtype, which further allows the tumor to grow and
proliferate without check. These phenotypes have been suggested to play a role in
tumor progression and metastasis and have also been shown to be modulated by
various stimuli in the tumor microenvironment, including exosomes. Exosomes are
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small, 40-150 nm vesicles that have been shown to be involved as an integral part of
inter-cellular communication, resulting in increased tumor progression, increased tumor
survival and increased immune evasion. Exosomes have been shown to play a role in
modulating macrophage phenotype from M1 to M2 in cancers such as glioblastoma,
melanoma, pancreatic cancer, colorectal cancer and breast cancer, but has not yet
been explored in osteosarcoma. It is our specific hypothesis that the exosomal cargo of
a metastatic osteosarcoma cell can modulate cellular signaling within macrophages,
thereby causing the development of a more tumor tolerant phenotype. We aim to
characterize the changes in macrophage phenotype and function in response to
metastatic osteosarcoma exosome uptake as well as determine the mechanism by
which these changes take place in vitro.
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CHAPTER THREE: METASTATIC OSTEOSARCOMA CELL EXOSOMES INHIBIT
THE TUMORICIDAL FUNCTIONS OF MACROPHAGES

This work is based upon “Exosomal Communication by Metastatic Osteosarcoma Cells
Modulates Alveolar Macrophages to an M2 Tumor-Promoting Phenotype and Inhibits
Tumoricidal Functions” by Wolf-Dennen, K, Gordon, N, Kleinerman, E, C. 2020.
OncoImmunology; presented with permission from OncoImmunology.

3.1: Introduction
Osteosarcoma is the most common primary malignancy of bone in children,
adolescents, and young adults [208]. Metastasis occurs almost exclusively to the lung,
and 5-year survival rates drop drastically, to less than 30%, once this occurs [209, 210].
The success of current chemotherapies has plateaued however, highlighting an
increasing clinical need to better understand this disease in order to identify new
therapeutic targets and improve patient outcomes. Characterizing and understanding
the biological properties that both permit and support osteosarcoma cells to grow and
thrive in the lung microenvironment may allow for the development of new therapies for
metastatic osteosarcoma. The tumor microenvironment is complex, comprising of
surrounding stromal cells, innate and adaptive immune cells, cancer cells, and
mesenchymal stem cells [119]. Recently, macrophages, an integral phagocyte of the
innate immune system, have been shown to be important to patient survival in
osteosarcoma and other cancers [105, 211].
Macrophages are professional phagocytes and are highly specialized in the
removal of dead or dying cells and cellular debris. They have also been shown to be
critical components of the tumor microenvironment [52, 211, 212]. There are two
41

classically accepted macrophage phenotypes: an antitumorigenic M1 phenotype and a
tumor promoting M2 phenotype. M1 macrophages have been shown to support the
adaptive immune response, targeting dead or dying cells as well as infectious agents,
and they are characterized by increased expression of inflammatory chemokines and
cytokines such as interleukins IL1 and IL6 and tumor necrosis factor alpha (TNFA) [52].
Additionally, M1 macrophages within osteosarcoma lung metastases have been shown
to correlate with better patient outcome [107, 211]. M2 macrophages are associated
with the development of an immunosuppressive microenvironment through the
expression of IL10 and transforming growth factor beta 2 (TGFB2) [52]. M2
macrophages have also been shown to promote cancer by enhancing tumor
invasiveness, angiogenesis, and metastasis [212]. Growing evidence suggests that a
high density of M2-like tumor-associated macrophages is associated with poor
prognosis and poor patient survival in many cancers [213]. In both primary and
metastatic osteosarcoma, macrophages located within the tumor microenvironment are
typically polarized to the M2-like subtype, which further allows the tumor to grow and
proliferate without check [211]. The M2 phenotype has been suggested to play a role in
tumor progression and metastasis and have also been shown to be modulated by
various stimuli in the tumor microenvironment, including exosomes [120].
Exosomes are small, 40- to 150-nm vesicles that have been shown to be an
integral part of intercellular communication, resulting in increased tumor progression
and immune evasion as well as prolonged tumor survival [121, 122, 125]. Exosomes
have also been shown to be released by a wide variety of cells, including cancer cells,
both in vitro and in vivo [122]. Like cells, exosomes possess a lipid bilayer membrane
that protects their contents, which include proteins, mRNAs, microRNAs, and genomic
DNA, and have been shown to play a critical role in intercellular signaling [122].
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Exosomes have also been shown to modulate macrophage phenotype in other cancers
such as glioblastoma, gastric cancer, melanoma, colorectal cancer, and breast cancer
[186, 187, 189-191, 214, 215]. Exosomes from non-metastatic melanoma cells have
been shown to stimulate an innate immune response via the recruitment of natural killer
cells and monocytes and to suppress metastasis in the lung in vivo [216]. In
osteosarcoma, exosomes have been shown to be related to migration, invasion, and
tumor progression, but the complex interplay between osteosarcoma cells and
macrophages has yet to be investigated [195, 202, 217].
Because a tumor-promoting microenvironment contains M2 macrophages, and
M2 macrophages are linked to poor outcomes in patients with osteosarcoma lung
metastases, we compared the extracellular communications between metastatic and
non-metastatic osteosarcoma cells and alveolar macrophages. It was our hypothesis
that metastatic osteosarcoma cells help to create a tumor-permissive environment by
exosomal communication. Our results highlight a potential extracellular mechanism by
which metastatic osteosarcoma cells communicate with alveolar macrophages to
suppress the innate immune response and reveal a potential new therapeutic
opportunity to improve the response of relapsed osteosarcoma in the lung to various
immunotherapies.

3.2: Results

3.2.1: Osteosarcoma cell exosomes have common exosome characteristics and
can be taken up by alveolar macrophages
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Non-metastatic and metastatic melanoma cell exosomes can have varying
effects on the cells of the immune system [216]. We therefore elected to compare the
effects of exosomes from murine osteosarcoma cells that form lung metastases and
those that do not. K7 osteosarcoma cells are non-metastatic and form only a primary
tumor. K7M3 osteosarcoma cells were derived from K7 cells [218] but, unlike K7 cells,
metastasize to the lung following intratibial injection. Dunn cells are also nonmetastatic, while DLM8 is the metastatic subline [219]. Exosomes were extracted from
all four cell types via differential centrifugation, size exclusion filtration, followed by
ultracentrifugation. Exosome size was evaluated and analyzed using nanoparticle
tracking analysis and transmission electron microscopy. Exosomes were found to be
within the acceptable size range (Figure 3A), were positive for CD9 expression (Figure
3B), and also featured a membrane bilayer characteristic consistent with the defining
features of exosomes. Exosomes were also shown to express exosomal marker CD81
but were not shown to express HSP90B1 or Calreticulin (Figure 3C), both markers of
cytoplasmic content. Exosomes from a normal fibroblast cell line were included as a
control (Figure 3C, Figure 4).
We next investigated whether mouse-derived alveolar macrophages could take
up exosomes derived from osteosarcoma cells and fibroblasts. Murine alveolar
macrophages (MHS cells) were cultured and incubated for 24 h with exosomes
extracted from K7, K7M3, Dunn, and DLM8 cells (Figure 5A) or from 3T3 cells (Figure
4C) and then labeled with CM-DiI red fluorescent dye. Cells were then imaged using an
IncuCyte S3 Live-Cell Analysis System. Uptake of exosomes from all osteosarcoma
cells and fibroblasts was demonstrated and confirmed by using labeled exosomes and
fluorescent microscopy (Figure 5B, Figure 4D).

44

A.

B.

K7M3 Exosome

DLM8 Exosome

K7 Exosome

C.

Dunn Exosome

45

Figure 3. Osteosarcoma cell exosomes exhibit exosome morphology and the
exosome markers CD9 and CD81. Exosomes were extracted from K7M3, K7, DLM8,
and Dunn osteosarcoma cells via ultracentrifugation. (A) Exosome size and
concentration were assessed via Nanosight analysis. (B) Transmission electron
microscopy and immunogold staining was used to analyze CD9 expression. Arrows
indicated positive CD9 expression. (C) Western blot analysis was used to evaluate
CD81, Calreticulin and HSP90B1 expression in K7M3, K7, DLM8, Dunn, and 3T3 cell
exosomes. MHS cells were used as a positive control.
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Figure 4. Fibroblast cell exosomes have the common exosome morphology,
express exosome marker CD9, and can be taken up by murine alveolar
macrophages. Fibroblast cell exosomes were extracted via ultracentrifugation. (A)
Exosome size and concentration were assessed via Nanosight analysis. (B) Fibroblast
cell exosomes were analyzed using transmission electron microscopy and immunogold
staining for CD9. (C, D) Fibroblast cell exosomes were extracted and then labeled with
Cell Tracker CM-DiI red fluorescent dye. Alveolar macrophages were cultured
overnight and then treated with labeled fibroblast cell exosomes for 24 h. The images
were analyzed using (C) the IncuCyte Live-Cell System at 20´ and the (D) Nikon
Eclipse Ti de-convolution inverted bright field and fluorescent microscope at 60´ under
oil immersion.

48

A. DiI Only Control

K7M3 Exosomes

200µm

200µm

200µm

DiI Only Control

DLM8 Exosomes

K7M3 Exosomes

200µm

K7 Exosomes

Dunn Exosomes

200µm

DLM8 Exosomes

Dunn Exosomes

Merged

Bright Field

DAPI

Osteosarcoma
Cell Exosomes

B.

K7 Exosomes

50µm

50µm

50µm

49

50µm

50µm

Figure 5. Alveolar macrophages can uptake osteosarcoma cell exosomes.
Osteosarcoma cell exosomes were extracted from non-metastatic K7 and Dunn cells
and from metastatic K7M3 and DLM8 cells via ultracentrifugation and then labeled with
Cell Tracker CM-DiI red fluorescent dye. Alveolar macrophages were cultured
overnight and then treated with labeled osteosarcoma cell exosomes for 24 h. Both
fluorescent and bright field images were collected using the (A) IncuCyte Live-Cell
System at 20´ and the (B) Nikon Eclipse Ti de-convolution inverted bright field and
fluorescent microscope at 60´ under oil immersion. Osteosarcoma cell exosomes are
shown in red and DAPI in blue. Bright field images are also included, as well as the
merged images from all three channels.
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3.2.2: Exosomes from metastatic osteosarcoma cells decreased macrophage
tumoricidal activity
Because macrophages are professional phagocytes and play an important role
in tumor cell recognition and killing through the phagocytic process, we investigated the
effect of exosomal uptake on three different macrophage functions [52, 53, 212]:
phagocytosis, efferocytosis, and cytotoxicity. Uptake of exosomes from K7M3 and
DLM8 cells led to a significant decrease in the phagocytic function of MHS alveolar
macrophages as compared to untreated control macrophages (Figure 6). Significant
inhibition was seen at twenty-four hours for MHS cells treated with K7M3 or DLM8
exosomes. By contrast, there was no significant change in phagocytosis following
uptake of exosomes from non-metastatic K7 or Dunn cells (Figure 6) or from 3T3 cells
(Figure 7A). When MHS cells were incubated with metastatic K7M3 or DLM8 cell
exosomes, efferocytosis was significantly decreased at twelve and thirty hours
respectively as compared to controls (Figure 8). By contrast, exosomes from nonmetastatic osteosarcoma cells (Figure 8) as well as exosomes derived from normal
fibroblasts (Figure 7B) did not decrease efferocytosis. Exosomes from K7 cells
significantly increased MHS cell efferocytosis at twenty-four hours while there was no
significant difference in MHS cells exposed to either Dunn cell or 3T3 cell exosomes.
Finally, uptake of exosomes from metastatic osteosarcoma cells (K7M3 or DLM8)
significantly decreased macrophage-mediated tumor cell killing (Figure 9). By contrast,
MHS cells incubated with K7 or Dunn cell exosomes (Figure 9) or with 3T3 cell
exosomes (Figures 7C and 7D) showed no decrease in macrophage-mediated tumor
cell killing. Indeed, macrophage-mediated tumor cell killing was significantly increased
following uptake of Dunn or 3T3 exosomes at twenty-four and forty-eight hours
respectively. MHS cells incubated with 3T3 exosomes showed enhanced cytotoxic
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activities against both DLM8 and K7M3 cells (Figure 7C) as well as against K7 and
Dunn cells (Figure 7D), and against normal 3T3 cells (Figure 7E). Taken together,
these data suggest that metastatic osteosarcoma cell exosomes inhibit the phagocytic
and cytotoxic functions of alveolar macrophages, while non-metastatic osteosarcoma
cell and normal fibroblast-derived exosomes do not.
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Figure 6. Metastatic osteosarcoma cell exosomes inhibit alveolar macrophage
phagocytosis. Alveolar macrophages (MHS cells) were cultured overnight and then
incubated with exosomes from osteosarcoma cells (non-metastatic K7 and Dunn;
metastatic K7M3 and DLM8) for 24 h. Osteosarcoma cells, labeled with IncuCyte
pHrodo labeling reagent, were then added to the MHS cell culture. Phagocytic activity
was determined using the IncuCyte S3 Live-Cell Analysis system and the data
analyzed by IncuCyte software. Significant inhibition (p<0.05) was seen at twenty hours
for K7M3 and DLM8.
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Figure 7. Normal fibroblast cell exosomes have no effect on phagocytosis or
efferocytosis, increase macrophage-mediated cytotoxicity. Alveolar macrophages
(MHS cells) were cultured overnight and incubated with fibroblast cell exosomes for 24
h. Fibroblast cells were then labeled with IncuCyte pHrodo labeling reagent and then
added to the MHS cell culture. (A) Phagocytosis and (B) efferocytosis were analyzed
using the IncuCyte S3 Live-Cell Analysis system. Gemcitabine was used as the
apoptosis-inducing reagent in order to measure efferocytosis. (C, D) Macrophagemediated tumor cell killing was measured in metastatic (C) DLM8 and K7M3 cells, and
non-metastatic (D) K7 and Dunn cells. Osteosarcoma cells were cultured overnight and
then labeled with the IncuCyte Caspase 3/7 green apoptosis reagent. MHS cells were
cultured overnight with fibroblast cell exosomes and were then added to the labeled
osteosarcoma cells. Cytotoxicity was determined using the IncuCyte S3 Live-Cell
Analysis system, and the data were analyzed by the IncuCyte software. Significant
enhancement (p< 0.05) was seen at forty hours for DLM8, K7M3 and Dunn, and at
twenty-four hours for K7. (E) Macrophage-mediated cytotoxicity was determined using
3T3 normal fibroblast cells. 3T3 cells were cultured overnight and then labeled with the
IncuCyte Caspase 3/7 green apoptosis reagent. MHS cells were cultured overnight with
fibroblast cell exosomes and were then added to the labeled fibroblast cells.
Cytotoxicity was determined using the IncuCyte S3 Live-Cell Analysis system, and the
data were analyzed by the IncuCyte software. Significant enhancement (p< 0.05) was
seen at thirty hours.
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Figure 8. Metastatic osteosarcoma cell exosomes inhibit alveolar macrophage
efferocytosis. MHS cells were cultured overnight and then incubated with exosomes
from the same four osteosarcoma cell lines for 24 h. Effercytosis is the process of
clearing dying apoptotic cells. Therefore, osteosarcoma cells, previously treated with
gemcitabine for 24 h at a dose that induced apoptosis were labeled with IncuCyte
pHrodo labeling reagent, were then added to the MHS cell culture. Efferocytosis was
determined by using the IncuCyte S3 Live-Cell Analysis system, and the data were
analyzed by the IncuCyte software. Significant inhibition (p<0.05) was seen at twelve
and thirty hours for K7M3 and DLM8 respectively. Significant enhancement (p<0.05)
was seen at twenty-four hours for K7.
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Figure 9. Metastatic osteosarcoma cell exosomes inhibit alveolar macrophagemediated tumor cell killing. To assess the effect of exosomes on macrophagemediated cytotoxicity, osteosarcoma cells were cultured overnight and then labeled
with the IncuCyte Caspase 3/7 green apoptosis reagent. MHS cells were cultured
overnight with exosomes from the four osteosarcoma cell lines and were then added to
the labeled osteosarcoma cells. Cytotoxicity was determined using the IncuCyte S3
Live-Cell Analysis system and the data were analyzed by the IncuCyte software. MHS
cells treated with PBS was used as a control. Significant inhibition (p<0.05) was seen
at twenty-four hours for K7M3 and DLM8. Significant enhancement (p<0.05) was seen
at twenty-four hours for Dunn.

61

To further validate these findings, we investigated the effect of exosomes from
non-metastatic and metastatic human osteosarcoma cells on macrophage function
using THP1, a human-derived monocyte cell line. THP1 cells were derived from the
peripheral blood and can be activated by PMA (phorbol 12-mystristate 13-acetate) into
macrophages. SAOS2 human osteosarcoma cells do not form lung metastases when
injected in vivo. LM7 cells were derived from SAOS2 cells but are metastatic to the
lung. SAOS2 and LM7 cell exosomes display common exosome characteristics such
as size (Figure 10A), the exosome marker CD81, as well as low levels of Calreticulin
and HSP90B1 (Figure 10B). Additionally, THP1 cells take up SAOS2 and LM7 cell
exosomes within twenty-four hours after activation (Figure 10C). Similar to our findings
using K7M3 and DLM8 exosomes, when THP1 cells were activated and then exposed
to LM7 cell exosomes, there was a significant decrease in phagocytic function as well
as macrophage-mediated tumor cell killing (Figure 11A). In contrast, when THP1 cells
were activated and exposed to SAOS2 exosomes, there was no effect on phagocytosis
and macrophage-mediated tumor cell killing (Figure 11B). These data confirm that
metastatic osteosarcoma cell exosomes inhibit the critical functions of macrophages
which may have an impact on tumor survival and metastatic growth in the lung.
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Figure 10. Human osteosarcoma cell exosomes have the common exosome
morphology, express exosome marker CD81, and can be taken up by activated
human macrophages. (A) Exosome size and concentration were assessed via
Nanosight analysis. (B) Western blot analysis was used to evaluate CD81, Calreticulin
and HSP90B1 expression in SAOS2 and LM7 cell exosomes. MHS cells were used as
a positive control. (C) Osteosarcoma cell exosomes were extracted from nonmetastatic SAOS2 cells and from metastatic LM7 cells via ultracentrifugation and then
labeled with Cell Tracker CM-DiI red fluorescent dye. Human THP1 monocytes were
cultured overnight, activated with 150 ng/mL of PMA and then treated with labeled
osteosarcoma cell exosomes for 24 h. Both fluorescent and bright field images were
collected using the IncuCyte Live-Cell System at 20´.
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Figure 11. Metastatic human osteosarcoma cell exosomes inhibit macrophage
phagocytosis and macrophage-mediated tumor cell killing. (A) Human monocytes
(THP1 cells) were cultured and activated with PMA (150 ng/mL) overnight and then
incubated with exosomes from human osteosarcoma cells (non-metastatic SAOS2;
metastatic LM7) for 24 h. Osteosarcoma cells, labeled with IncuCyte pHrodo labeling
reagent, were then added to the THP1 cell culture. Phagocytic activity was determined
using the IncuCyte S3 Live-Cell Analysis system and the data analyzed by IncuCyte
software. The exosomes from LM7 cells induced a significant inhibition (p<0.05) in
phagocytic activity at twenty hours. (B) Osteosarcoma cells were cultured overnight
and then labeled with the IncuCyte Caspase 3/7 green apoptosis reagent. THP1 cells
were activated overnight with PMA (150 ng/mL) and then exposed to exosomes from
the two osteosarcoma cell lines and were then added to the labeled osteosarcoma
cells. Cytotoxicity was determined using the IncuCyte S3 Live-Cell Analysis system and
the data were analyzed by the IncuCyte software. THP1 cells treated with PBS was
used as a control. Significant inhibition (p<0.05) in cytotoxic activity was seen at
twenty-four hours for the THP1 cells incubated with LM7 exosomes.
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3.3: Discussion
The data presented demonstrated that murine alveolar macrophages take up
exosomes from both non-metastatic and metastatic murine osteosarcoma cells and
from normal fibroblasts. Uptake of metastatic osteosarcoma cell exosomes resulted in
decreased phagocytosis, efferocytosis, and macrophage-mediated tumor cell killing. In
contrast, non-metastatic osteosarcoma cell exosomes did not decrease phagocytosis,
efferocytosis, or macrophage-mediated tumor cell killing. The inhibitory effect of
exosomes from the metastatic cells was also seen when human macrophages were
incubated with exosomes from human LM7 metastatic cells but not with non-metastatic
parental SAOS2 cells.
The control curves in the experiments with DLM8 and Dunn cells (Figure 8) were
noted to be different. This may be due to the differences in the baseline activity of
control untreated MHS cells to phagocytose Dunn versus DLM8 cells. The critical
finding however is that regardless of the baseline activity, decreased phagocytosis of
DLM8 cells was seen when MHS cells were treated with DLM8 exosomes for 24 h and
then incubated with labeled DLM8 cells. There was no difference in phagocytic activity
when MHS cells were incubated with Dunn exosomes. Thus, uptake of exosomes from
the metastatic DLM8 cells compromised macrophage function as defined by
phagocytosis, efferocytosis and cytotoxic activity. We also noted an increase in
cytotoxic function following incubation of MHS cells with exosomes from the nonmetastatic Dunn cells (Figure 9). We have no explanation for why Dunn cells
increased MHS-mediated cytotoxicity at this time. However, once again this data
shows that the compromised macrophage function is being specifically induced by the
metastatic exosomes and not merely due to the uptake of exosomes from any
osteosarcoma cells.
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It is important to note that alveolar macrophages specifically function to keep
airspaces sterile, despite the exposure of the alveolar microenvironment to a wide array
of potentially infectious and inflammatory particulates. Alveolar macrophages play a
crucial role in preserving the balance between inflammatory and immunosuppressive
responses in the lung in order to maintain tissue homeostasis [49]. The lung alveolar
membrane is the largest surface of the body in contact with the outside environment
and is thus exposed to a diverse array of microbes and organic and inorganic
particulates [49]. Complex cell signaling pathways are responsible for the recognition of
potentially harmful materials and subsequent activation or suppression of the immune
system. The innate immune system is active and immediately responsive to harmful
stimuli. Alveolar macrophages account for approximately 95% of airspace leukocytes,
while the other 5% comprises neutrophils and lymphocytes [49]. Alveolar macrophages
thus act as the sentinel phagocytic cell of the innate immune system in the lung and are
avidly phagocytic in response to inhaled particulates that reach the alveolar spaces of
the lung [49]. In addition to phagocytosis, alveolar macrophages also function in the
process of efferocytosis or the phagocytosing of dead or dying cells [220]. Efferocytosis
allows dead cells to be removed from the microenvironment before their membrane
integrity is breached and their contents leak into the surrounding tissue [220]. This
process prevents exposure of tissue to toxic enzymes, oxidants, and other intracellular
components such as caspases and proteases [220]. These inflammatory processes
may or may not be beneficial to tumor cell survival and growth. Macrophages also are
able to selectively and effectively kill a wide variety of neoplastic cells in a contactdependent, non-phagocytic manner [221]. Alveolar macrophages may play a role that
is unique in the context of metastatic osteosarcoma and our data suggests that they
may act in a tumor supportive manner.
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In summary, our results show that metastatic osteosarcoma cells can
communicate with innate immune cells such as macrophages within the tumor
microenvironment using exosomes. Taken together, our data show that metastatic
exosomes, but not non-metastatic or normal exosomes, modify macrophage function
which in turn create a more tumor-permissive environment protecting the tumor cells
from immune-mediated killing.

Table 1: Metastatic osteosarcoma cell exosomes decrease macrophage function.
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CHAPTER FOUR: METASTATIC OSTEOSARCOMA CELL EXOSOMES
MODULATE ALVEOLAR MACROPHAGES TO AN M2-PROMOTING PHENOTYPE
VIA TGFB2

This work is based upon “Exosomal Communication by Metastatic Osteosarcoma Cells
Modulates Alveolar Macrophages to an M2 Tumor-Promoting Phenotype and Inhibits
Tumoricidal Functions” by Wolf-Dennen, K, Gordon, N, Kleinerman, E, C. 2020.
OncoImmunology; presented with permission from OncoImmunology.

4.1: Introduction
Preliminary data presented in chapter three suggested functional changes in
macrophages exposed to metastatic osteosarcoma cell exosomes. Macrophages are
professional phagocytes and are highly specialized in removing dead or dying cells and
cellular debris. Phagocytosis is a molecularly diverse process that includes the
activation of a variety of receptors and cell signaling pathways [220]. As such, there are
a wide variety of interactions that result in either “eat me” signals or “don’t eat me”
signals. In order to begin to characterize the functional changes that we observed, we
elected to investigate markers of M1 and M2 macrophages due to the fact that M1 and
M2 macrophages behave differently in their ability to phagocytose cellular material [50].
M1 macrophages are avidly phagocytic while M2 macrophages are not [50].
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4.2: Results

4.2.1: Metastatic osteosarcoma cell exosomes increased expression of M2related cytokines and chemokines
We quantified markers of M2-like macrophages following exposure to
osteosarcoma cell exosomes. Exosomes from K7M3 and DLM8 cells resulted in
significant increases in expression levels of IL10, TGFB2, and CCL22 (Figure 12),
cytokines and chemokines associated with the M2 phenotype, compared to control.
MHS cells treated with exosomes from non-metastatic K7 or Dunn cells (Figure 12) or
3T3 cells (Figure 13) did not show increased expression of IL10, TGFB2, and CCL22.
We also assessed CXCL9, CXCL10, IL1B and TNFa, markers of M1 macrophages
(Figure 14). There was a significant decrease in CXCL9 expression in MHS cells
exposed to DUNN and K7M3 exosomes compared to normal exosome control. There
was also a significant decrease in CXCL10 expression in response to DUNN exosome
uptake. Additionally, there was a significant decrease in IL1B expression in response to
DUNN and DLM8 exosomes, as well as a significant increase in expression in
response to K7 exosome uptake. Lastly, there was significant decrease in TNFa
expression in response to DUNN, K7 and K7M3 exosome uptake. These data show
that exosomes from metastatic cells had little to no effect on the expression of M1
markers. Taken together, these data indicate that metastatic osteosarcoma cell
exosomes induce an M2-like phenotype.
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Figure 12. Metastatic osteosarcoma cell exosomes significantly increase mRNA
expression of M2 macrophage–related cytokines and chemokines. Alveolar
macrophages (MHS cells) were cultured overnight and then incubated with exosomes
from osteosarcoma cells (non-metastatic K7 and Dunn; metastatic K7M3 and DLM8)
for 24 h. The cells were harvested, total RNA was collected, and cDNA conversion was
performed. Hf3fa was used as a loading control. Expression of IL10, TGFB2, and
CCL22 mRNAs was quantitated by qPCR. * indicates a p value of < 0.05. ** indicates a
p value < 0.005. *** indicates a p vale < 0.0005.
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Figure 13. Normal fibroblast cell exosomes decrease the expression of M2associated factors. MHS cells were cultured overnight and then exposed to fibroblast
cell exosomes for 24 h. The cells were harvested, total RNA collected, and cDNA
conversion performed. Hf3fa was used as a loading control. mRNA expression of IL10,
TGFB2, and CCL22 was quantitated by qPCR. * indicates a p value of < 0.05. ***
indicates a p vale < 0.0005.
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Figure 14. Osteosarcoma cell exosomes modulate expression of M1 related
markers in a manner that is independent of the metastatic status of the
osteosarcoma cell. (A.) MHS cells were cultured overnight and then exposed to
osteosarcoma and fibroblast cell exosomes for 24 h. The cells were harvested, total
RNA collected, and cDNA conversion performed. Hf3fa was used as a loading control.
mRNA expression of CXCL9, CXCL10, IL1B and TNFa was quantitated by qPCR. *
indicates a p value of < 0.05. (B).
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4.2.2: Exosomes from metastatic osteosarcoma cells decreased phagocytosis in
alveolar macrophages through the induction of TGFB2
Because both TGFB2 and IL10 expression were elevated in MHS cells following
uptake of metastatic osteosarcoma cell exosomes, we next investigated the secretion
rate of both cytokines in response to osteosarcoma exosome uptake. When MHS cells
were exposed to DLM8 exosomes, there was a significant increase in IL10 levels
compared to MHS cells exposed to Dunn cell exosomes (Figure 15A). However, there
was no significant difference in IL10 levels secreted by MHS cells exposed to K7 or
K7M3 cell exosomes. By contrast, the uptake of K7M3 and DLM8 exosomes, induced a
significant increase in TGFB2 levels as compared to MHS cells exposed to K7 or Dunn
exosomes (Figure 15B). To determine whether TGFB2 mediated the decreased
macrophage activity induced by the metastatic K7M3 exosomes, (Figure 15C) or DLM8
(Figure 15D), MHS cells were treated with K7M3 or DLM8 exosomes with or without
neutralizing a-TGFB2 antibody. Significant inhibition (p<0.05) in phagocytic activity was
seen at twelve hours for the MHS cells incubated with both K7M3 and DLM8 exosomes
as compared to control. By contrast, MHS cells incubated with K7M3 or DLM8
exosomes plus anti-TGFB2 were similar to control. The baseline phagocytic activity
was not statistically different (p> 0.05) in the cells treated with anti-TGFB2 (Figure 15C,
D). Treatment with anti-TGFB2 prevented the decreased phagocytosis induced by the
metastatic exosomes. Taken together, these data suggest that metastatic
osteosarcoma cell exosomes induce an immunosuppressive phenotype through the
secretion of TGFB2.
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Figure 15. Induction of TGFB2 by exosomes from K7M3 and DLM8 metastatic
cells plays a role in inhibiting macrophage function. Alveolar macrophages (MHS
cells) were cultured overnight and then incubated with exosomes from osteosarcoma
cells (non-metastatic K7 and Dunn; metastatic K7M3 and DLM8) for 48 h. IL10 (A) and
TGFB2 (B) secretion in culture medium was measured by ELISA. *** indicates a p vale
< 0.0005 (C,D) Alveolar macrophages (MHS cells) were cultured overnight and then
incubated with exosomes from metastatic K7M3 (C) cells and DLM8 (D) cells with or
without TGFB2 antibody (0.1ug/mL) for 24 h. Osteosarcoma cells, labeled with
IncuCyte pHrodo labeling reagent, were then added to the MHS cell culture. Phagocytic
activity was determined using the IncuCyte S3 Live-Cell Analysis system and the data
analyzed by IncuCyte software. Significant inhibition (p<0.05) in phagocytic activity was
seen at twelve hours for the MHS cells incubated with both K7M3 and DLM8 exosomes
as compared to control. There were no significant differences observed at twelve hours
between control and K7M3 or DLM8 exosomes plus anti-TGFB2.
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4.3: Discussion
In summary, metastatic osteosarcoma cell exosomes induced increased mRNA
expression of IL10, TGFB2, and CCL22, which are cytokines and chemokines
associated with M2 macrophages. This was not seen using the non-metastatic
osteosarcoma cell exosomes. In addition, metastatic osteosarcoma cell exosomes
induced increased production of TGFB2 protein, which is a key modulator of immune
suppression within the tumor microenvironment [222]. Finally, inhibition of TGFB2
reversed the suppressive phagocytic activity in alveolar macrophages induced by the
metastatic osteosarcoma cell exosomes, suggesting that TGFB2 plays a key role in the
inhibition of macrophage function in response to metastatic osteosarcoma cell
exosome uptake. These data taken together support the concept that metastatic
osteosarcoma cells can induce an immunosuppressive tumor microenvironment
through the secretion of exosomes.
It is now established that macrophage polarization toward an M2 phenotype and
M2 macrophage predominance in osteosarcoma lung metastases contribute to the
pathogenesis and poor prognosis of osteosarcoma [105, 211]. Consequently,
identifying mechanisms that trigger M2 macrophage polarization has the potential to
reveal a novel treatment target for patients with relapsed osteosarcoma in the lung.
Since M2 macrophages have been shown to hinder or inhibit responses to CAR T-cells
and checkpoint inhibitors, understanding and targeting M2 polarization may also
improve the efficacy of immunotherapy. Despite the translational relevance, however,
our understanding of how osteosarcoma cells interact with the lung microenvironment
to make it tumor permissive is limited. In this study, we identified a potential mechanism
by which metastatic osteosarcoma cells control the lung microenvironment to inhibit the
immune response. We demonstrated that exosomes from metastatic osteosarcoma
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cells are different than exosomes from non-metastatic or normal cells in that they
induced an M2 phenotype characterized by increased expression of IL10, TGFB2, and
CCL22 inhibited macrophage-mediated phagocytosis, efferocytosis, and cytotoxicity,
functions that are critical to the successful elimination of tumor cells. In alveolar
macrophages exposed to exosomes from non-metastatic K7 or Dunn cells or from
normal fibroblasts, we saw no induction of IL10, TGFB2, and CCL22 expression, and
no inhibition of phagocytosis, efferocytosis, or macrophage-mediated tumor cell killing.
Additionally, the metastatic exosomes induced an increase in the secretion of TGFB2,
a molecular mediator of tumor-induced immunosuppression [29]. Finally, inhibition of
TGFB2 in alveolar macrophages reversed the immunosuppressive activity induced by
metastatic osteosarcoma cell exosomes.
We recently showed the critical nature of macrophage polarization to the M1
phenotype in the anti-tumor response to anti-PD-1 therapy [116]. Anti-PD-1 therapy
induced regression of microscopic osteosarcoma lung metastases and redirected
macrophages within the metastases from an M2 to an M1 phenotype [116].
Therapeutic efficacy was shown to be mediated by macrophages and not natural killer
cells or T cells [116]. Other investigators have also demonstrated the therapeutic
potential of targeting M2 macrophages within the tumor microenvironment. Combining
anti-PD-1 with a selective HDAC6 inhibitor significantly decreased the M2 macrophage
population and reduced tumor growth [223]. It has also been shown that an agonist
anti-CD40 antibody redirected macrophages toward the M1 phenotype, leading to reestablishment of immune surveillance and reduction in pancreatic tumor volume [213].
Furthermore, anti-CD47 therapy resulted in functional skewing of macrophages to an
M1 phenotype, which enhanced the antitumor responses [224]. Blocking the CSF1/CSF-1R signaling axis resulted in reprogramming of M2 macrophages, which
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stimulated antitumor immunity in pancreatic ductal adenocarcinoma [212]. Finally,
liposome-encapsulated muramyl tripeptide, a synthetic analogue of muramyl dipeptide,
which activates macrophages and augments the M1 phenotype, had a beneficial
impact on osteosarcoma patient survival [114].
Additionally, macrophages secrete different cytokines and chemokines
depending upon their phenotype, which can kill tumor cells or support their growth. M1
macrophages secrete a diverse array of inflammatory cytokines and chemokines,
whereas M2 macrophages secrete immunosuppressive cytokines and chemokines,
such as IL10 and CCL22, as well as TGFB2 [225]. Therefore, the capacity of tumor
cells in the lung to control the polarization of alveolar macrophages away from the M1
phenotype to the M2 phenotype is beneficial to the tumor’s successful survival.
TGFB is a potent homeostatic regulator of the anti-inflammatory response and
has been shown to display immunosuppressive activities toward various components of
the immune system [222]. The major physiological function of TGFB is to constrain and
inhibit the expansion and function of many components of the immune system,
including both adaptive and innate immunity. TGFB is a crucial component within the
tumor microenvironment, which has revealed roles in both immune evasion and poor
responses to cancer immunotherapy [222]. Malfunctions in TGFB signaling result in
immune dysfunction and has been associated with cancer progression. TGFB also
controls adaptive immunity by inhibiting the generation and function of antigen
presenting dendritic cells and effector T cells. TGFB also modulates innate immunity by
inhibiting natural killer cell function as well as the complex behavior of neutrophils and
macrophages [222]. In mice lacking TGFB type II receptor expression, activation of
alveolar macrophages to the M2 phenotype was inhibited, suggesting a critical role for
TGFB signaling in alveolar macrophage polarization. There are three isoforms of
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TGFB: TGFB1, TGFB2, TGFB3, but the functions of these isoforms in macrophages
are not well understood [222, 226]. When TGFB2 was inhibited through the use of an
antisense oligonucleotide, lung metastases of breast and kidney tumors were reduced
in part through the re-education of M2 macrophages to the M1 antitumor phenotype
[227]. Furthermore, TGFB1 and TGFB2 were found to be differentially regulated in
central nervous system and peripheral nerve injury, and TGFB2 was the principal
cytokine that controlled microglia and macrophage phagocytic function, rather than
TGFB1 [228]. Finally, exosomes produced by mesenchymal stem cells have been
shown to contain TGFB and drive differentiation of myeloid cells to an
immunosuppressive M2 phenotype in breast cancer [229]. Our data suggest that
metastatic osteosarcoma cell exosomes or factors within the metastatic osteosarcoma
cell exosomes induce TGFB2 signaling within alveolar macrophages, which may
redirect M1 alveolar macrophages to the M2 phenotype and thereby modulate
macrophage-mediated phagocytosis, efferocytosis, and tumor cell killing.
The exact mechanism by which exosomes control this dynamic change is
unclear, but it appears to involve the upregulation of TGFB2 signaling. While we
understand that this data is derived in vitro and does not necessarily equate to what
may occur in vivo, to our knowledge, this is the first study of its kind to demonstrate that
communication within the osteosarcoma tumor microenvironment may differ depending
on the metastatic status of a tumor cell. Understanding how tumor cells communicate
with and control the microenvironment will assist in discovering why patients with
osteosarcoma have shown little or no response to immunotherapy and may help in
designing combination approaches to block this pathway during immunotherapy. The
data from this study together with our previously published data showing that M1
macrophages are critical in the antitumor response to anti-PD-1 [116] as well as
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previously published data indicating that the inhibition of TGFB2 can re-educate M1
macrophages to an M2 phenotype [227] suggest that targeting TGFB2 may improve
macrophage M1 function and response to treatment by redirecting tumor-associated
macrophages from the M2 to the M1 phenotype.
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CHAPTER FIVE: ANCILLARY DATA

5.1: Investigation of global genetic expression data of alveolar macrophages
exposed to metastatic and non-metastatic osteosarcoma cell exosomes

In order to investigate the genetic changes that occur in alveolar macrophages
in response to metastatic exosome uptake, RNA sequencing was performed on MHS
cells exposed to DUNN, DLM8, K7 and K7M3 exosomes (Figure 16). Statistical
significance cannot be evaluated due to the fact that only one biological replicate of
each sample was sequenced, but there are a number of cancer and immune related
pathways that were modulated upon exposure to metastatic and non-metastatic
osteosarcoma cell exosomes that may warrant future study (Table 1). Of note, ARG2,
SNAI1 and CD22 were upregulated in MHS cells exposed to metastatic osteosarcoma
cell exosomes (Figure 17). Additionally, RAC1, KRAS and RAF1 were shown to be
downregulated in MHS cells exposed to metastatic osteosarcoma cell exosomes
(Figure 18). In order to reach statistical significance, this investigation should be
performed again in three biological replicates in order to eliminate the possibility of
false positives and false negatives. Additionally, the significant upregulation of SNAI1
and ARG2 were validated in three biological replicates via qPCR (Figure 19 and 20).
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Figure 16. Uncommon genes between alveolar macrophages exposed metastatic
and non-metastatic osteosarcoma exosomes. MHS cells were exposed to K7M3,
K7, DUNN and DLM8 exosomes for twenty-four hours. The cells were harvested, total
RNA was collected, and cDNA conversion was performed. RNA sequencing was
performed at the core MDACC Science Park NGS. 1. Metastatic = “UP” & nonmetastatic = “DOWN” (n = 234) 2. Metastatic = “DOWN” & non-metastatic = “UP” (n =
274)
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Figure 17: Top up-regulated genes in alveolar macrophages exposed to
metastatic exosomes.
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Figure 18: Top down-regulated genes in alveolar macrophages exposed to
metastatic exosomes.
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GENE
NAME

Metastatic

Non-metastatic

Rac1

DOWN

UP

Kras
Epas1
Gng2

DOWN
DOWN
DOWN

UP
UP
UP

Raf1

DOWN

UP

Wnt3
Flt4
Bcar1

DOWN
DOWN
DOWN

UP
UP
UP

Cd101

DOWN

UP

Cd200r4
F11r
Smad4
H2-Oa

DOWN
DOWN
DOWN
DOWN

UP
UP
UP
UP

Lag3
Mid2
Myom2
Nxpe3
Pdk2
Smurf2
Nexn

DOWN
DOWN
DOWN
DOWN
DOWN
DOWN
DOWN

UP
UP
UP
UP
UP
UP
UP

Tgm4

DOWN

UP

Cd22
Col4a2
Csf2ra
Cdkn2b
Gng8
Pml
Ralgds

UP
UP
UP
UP
UP
UP
UP

DOWN
DOWN
DOWN
DOWN
DOWN
DOWN
DOWN

Vegfc
Wnt9a
Trim21

UP
UP
UP

DOWN
DOWN
DOWN

Cd48
Cxcr6
Csf2ra
Arhgef16
Rasa1

UP
UP
UP
UP
UP

elevated levels associated with
enhanced efferocytosis
high MEK-ERK activation promotes
M1 polarization
high MEK-ERK activation promotes
M1 polarization
in cancer, downregulation inhibits
cancer cell proliferation and migration
signaling inhibits T cell proliferation
via IL-10
inhibitory receptor, inhibit iNos,
TNFa, interferons
involved in TGFB signaling
expression on T cells can suppress
macrophage function

downregulated in M2 macrophages
overexpression increases ability to
adhere in cancer cells
Inhibition restores microglia
phagocytosis

can recruit TAM via paracrine
signaling
expression can severely compromise
NK cell response, "missing-self"

DOWN
DOWN
DOWN
DOWN
DOWN
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Itga7
Itgb4
Myb

UP
UP
UP

DOWN
DOWN
DOWN

Arg2

UP

DOWN

Btnl1

UP

DOWN

Cntn1
Icam5
Lgi1
Mag
Ndnf
Oscar
Prtg
Robo2

UP
UP
UP
UP
UP
UP
UP
UP

DOWN
DOWN
DOWN
DOWN
DOWN
DOWN
DOWN
DOWN

Tnfsf18
Fcnb

UP
UP

DOWN
DOWN

Snai1

UP

restricts iNOS, deletion leads to
enhanced M1 activation
found in APCs, upregulation inhibits
T cell proliferation by arresting cell
cycle
cell adhesion, immunoglobulin family,
overexpression promotes growth and
metastasis
cell adhesion marker

TNF family, inhibit NK cells, shown to
promote CD4+ regulatory T cells
overexpression promotes M2 by
delivering mir-21 abundant
exosomes

DOWN

Table 2: List of top upregulated and downregulated cancer and immune-related
genes in alveolar macrophages exposed to metastatic and non-metastatic
exosomes. Metastatic = MHS cells treated with either K7M3 or DLM8 exosomes. Nonmetastatic = MHS cells treated with either K7 or DUNN exosomes.
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Figure 19: Validation of ARG2 elevation. Alveolar macrophages (MHS cells) were
cultured overnight and then incubated with exosomes from metastatic K7M3 and DLM8
osteosarcoma cells for 24 h. The cells were harvested, total RNA was collected, and
cDNA conversion was performed. Hf3fa was used as a loading control. Expression of
ARG2 was quantitated by qPCR. * indicates a p vale < 0.05 and was considered
significant by student’s t-test.

Figure 20: Validation of SNAI1 elevation. Alveolar macrophages (MHS cells) were
cultured overnight and then incubated with exosomes from metastatic K7M3 and DLM8
osteosarcoma cells for 24 h. The cells were harvested, total RNA was collected, and
cDNA conversion was performed. Hf3fa was used as a loading control. Expression of
SNAI1 was quantitated by qPCR. * indicates a p vale < 0.05 and was considered
significant by student’s t-test.
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5.2: Quantification of exosome uptake in alveolar macrophages

MHS cells were incubated with labeled osteosarcoma and fibroblast exosomes
and the rate of uptake was quantified over 24 hours (Figure 21). MHS cells took up DLM8
exosomes the fastest but at a similar level to 3T3 exosomes. Even though the rate of
3T3 exosome uptake was increased, we observed no decrease in macrophage function
in response to exosome uptake (Figure 7). In addition, there was no significant difference
between the rate of uptake between K7M3 and K7 exosomes. Therefore, we conclude
that the decrease in macrophage function after exposure to metastatic exosomes is not
due to differences in the rate of exosome uptake between non-metastatic or metastatic
osteosarcoma cell-derived exosomes.
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Figure 21: Quantification of exosome uptake over time in alveolar macrophages.
Osteosarcoma cell exosomes were extracted from non-metastatic K7 and Dunn cells
and from metastatic K7M3 and DLM8 cells and fibroblast exosomes from 3T3 cells via
ultracentrifugation and then labeled with Cell Tracker CM-DiI red fluorescent dye.
Alveolar macrophages were cultured overnight and then treated with labeled
osteosarcoma cell exosomes for 24 h. Both fluorescent and bright field images were
collected using the IncuCyte Live-Cell System at 20x and the data were analyzed by the
IncuCyte software.
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5.3: Investigation of the IL10 pathway

Because IL10 expression was elevated in MHS cells exposed to metastatic
osteosarcoma cell exosomes, we investigated the downstream cell signaling of the
IL10 receptor, which includes activation of Jak1 and Stat3 [230]. Upon exposure to
exosomes from metastatic K7M3 and DLM8 cells, Jak1 and Stat3 mRNA expression
was significantly elevated (Figure 22A, 22B). Additionally, the increased expression of
both Jak1 and Stat3 was maintained for 48 h (Figure 23). MHS cells treated with
exosomes from non-metastatic K7 or Dunn cells (Figure 22C) and 3T3 cells (Figure 23)
did not show increased expression of Jak1 and Stat3. However, when IL10 secretion
levels were evaluated, it was found that there was no significant difference in protein
secretion levels in MHS cells exposed to K7 and K7M3 exosomes, but there was a
significant increase in IL10 secretion levels in MHS cells exposed to DLM8 exosomes
when compared to MHS cells exposed to DUNN cell exosomes (Figure 15A). Upon
further evaluation of the IL10 signaling pathway, it was found that STAT3
phosphorylation was reduced in M2 macrophages that were treated with both IL4 and
IL13 (classical inducers of the M2 phenotype), as well as macrophages exposed to
metastatic osteosarcoma cell exosomes (Figure 24). This data suggests that the IL10
signaling pathway is not responsible for the functional differences seen in alveolar
macrophages exposed to metastatic osteosarcoma cell exosomes.
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Figure 22. Exosomes from metastatic osteosarcoma cells induce expression of
Jak1 and Stat3. Alveolar macrophages (MHS cells) were cultured overnight and then
incubated with exosomes from osteosarcoma cells (non-metastatic K7 and Dunn;
metastatic K7M3 and DLM8) for 24 h. The cells were harvested, total RNA was
collected, and cDNA conversion was performed. Hf3fa was used as a loading control.
Jak1 and Stat3 mRNAs were quantitated by qPCR. * indicates a p value of < 0.05. **
indicates a p value < 0.005. *** indicates a p vale < 0.0005 and was considered
significant by student’s t-test. Untreated MHS cells were used as a control.
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Figure 23. Alveolar macrophages incubated with exosomes from metastatic
osteosarcoma cells maintain increased expression of JAK1 and STAT3 over 48 h.
Alveolar macrophages (MHS cells) were cultured overnight and then incubated with
exosomes from metastatic K7M3 and DLM8 osteosarcoma cells for 24 and 48 h. The
cells were harvested, total RNA was collected, and cDNA conversion was performed.
Hf3fa was used as a loading control. Expression of Jak1 and Stat3 was quantitated by
qPCR. *** indicates a p vale < 0.0005 and was considered significant by student’s ttest.
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Figure 24. Alveolar macrophages exposed to metastatic osteosarcoma cell
exosomes decrease phospho-STAT3 levels similar to M2 macrophages.
Western blot analysis was used to evaluate phospho-STAT3, STAT3 and B-actin
expression in MHS cells exposed to K7M3, K7, DLM8, DUNN and 3T3 exosomes for
twenty four hours. MHS cells exposed to IL4 and IL13 (40ng/mL) was used as a
positive control and represent M2 macrophages. Densitometry is presented in the
second panel.
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5.4: ELISA of M1-related markers

Using ELISA, four markers of M1 macrophages were evaluated in MHS cells
treated with K7M3, K7, DLM8, and Dunn cell exosomes (Figure 25). There were no
significant differences in IFN-g, IL1B, or TNFa levels in MHS cells treated with
osteosarcoma cell exosomes when compared to control. IL-6 was significantly
decreased in MHS cells exposed to DUNN cell exosomes and significantly increased in
MHS cells exposed to K7M3 exosomes. This data suggests that neither non-metastatic
nor metastatic osteosarcoma exosomes induce an M1-like phenotype in alveolar
macrophages.

99

2.0

1.0
0.5

3
7M

M
3
K7

K7

DL
M

8

0.0
3T

3
7M
K

K

8
LM
D

N
N
U
D

7

0.0

0.5

NN

0.5

1.0

DU

1.0

*

1.5

3

1.5

3

7

IL6

2.0

3T

K

8
LM

IFNg
Fold Change (normalized to
non-metstatc control)

K

D

D

N
N

3T

7M

3

3

0.0

K

K

8
D

LM

N
N
U
D

3T

7

0.0

1.5

U

0.5

Fold Change (normalized to
non-metstatc control)

1.0

2.0

Fold Change (normalized to
non-metstatc control)

TNFa

1.5

3

Fold Change (normalized to
non-metstatc control)

IL1B

Figure 25. Metastatic exosomes do not induce an M1-like phenotype in alveolar
macrophages. Using ELISA, four markers of M1 macrophages (IFN-g, TNFa, IL-6 and
IL1b) were evaluated in MHS cells treated with K7M3, K7, DLM8, Dunn and 3T3 cell
exosomes for forty-eight hours. * indicates a p value of < 0.05 and was considered
significant by student’s t-test.
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5.5: ELISA of additional TGFB isoforms

Using ELISA, two additional isoforms of TGFB were evaluated in MHS cells
treated with K7M3, K7, DLM8, and Dunn cell exosomes (Figure 26). There were no
significant differences in TGFB1 or TGFB3 levels in MHS cells treated with K7M3 cell
exosomes when compared to non-metastatic control. Both TGFB1 and TGFB3 was
statistically increased in MHS cells treated with DLM8 exosomes as compared to MHS
cells treated with DUNN cell exosomes with a p value < 0.05. This data suggests that
metastatic osteosarcoma exosomes do not induce significant differences in TGFB1 and
TGFB3.

Figure 26. Metastatic exosomes do not induce significant differences in TGFB1
and TGFB3. Using ELISA, both TGFB1 and TGFB3 were evaluated in MHS cells
treated with K7M3, K7, DLM8, and Dunn cell exosomes for forty-eight hours. ***
indicates a p value of < 0.0005 and was considered significant by student’s t-test.
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5.6: Genetic expression of M2-related markers in response to IL4 and IL4 and
IL13 combination.

To investigate the changes in expression to a known M2-macrophage inducer,
we incubated MHS cells with IL-4 (40ng/mL), an M2 inducing cytokine (Figure 27A).
Significant increases in IL10, TGFB2 and CCL22 were seen when MHS cells were
treated with IL4 as compared to control. We also investigated the combination of IL4
(40ng/mL) and IL13 (40ng/mL) and assessed IL10, TGFB2 and CCL22 gene
expression (Figure 27B). Significant increases in IL10, TGFB2 and CCL22 were seen
when MHS cells were treated with IL4 and IL13 as compared to control.

Figure 27: IL4 and the combination of IL4 and IL13 induces an M2-like phenotype
in alveolar macrophages. MHS cells were cultured overnight and then treated with (A)
IL4 for 24 h and (B) IL4 and IL13 for 24 h. The cells were harvested, total RNA
collected, and cDNA conversion performed. Hf3fa was used as a loading control.
mRNA expression of Il10, Tgfb2, and Ccl22 was quantitated by qPCR. * represents a p
value < 0.05 and was considered significant by student’s t-test.
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5.7: Investigation of other important pathways related to phagocytosis

We have investigated a number of cellular signaling pathways in order to
determine the genes modulated by exosomes from non-metastatic or metastatic
osteosarcoma cells. IL4 signaling increases the expression of ARG1, which is
associated with an increase in arginine metabolism. In the context of our study, ARG1
mRNA expression was evaluated and there was a significant decrease in expression in
MHS exposed to K7M3 exosomes as compared to control (Figure 28). Additionally, no
differences were seen in RHOA mRNA expression (Figure 28). Furthermore, there was
a significant decrease in both SIRPa and CD47 expression compared to control (Figure
28). Both PD-1 and PD-L1 mRNA expression on macrophages exposed to
osteosarcoma cell exosomes were evaluated and no significant differences were
observed (data not shown).
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Figure 28 - Evaluation of other pathways related to phagocytosis. MHS cells were
cultured overnight and then treated with K7M3 exosomes for 24 h. The cells were
harvested, total RNA collected, and cDNA conversion performed. Hf3fa was used as a
loading control. mRNA expression of ARG1, RHOA, SIRPa and CD47 was quantitated
by qPCR. * represents a p value < 0.05 and was considered significant by student’s ttest.
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5.8: Investigation of other important macrophage functions

Proliferation and migration were assessed on MHS cells exposed to
osteosarcoma cell exosomes using functional live-cell IncuCyte assays (Figure 29).
There were no significant differences seen in macrophage proliferation or migration in
response to non-metastatic or metastatic osteosarcoma cell exosome uptake.
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Figure 29 - Metastatic osteosarcoma cell exosomes do not affect alveolar
macrophage proliferation or migration. Alveolar macrophages (MHS cells) were
cultured overnight and incubated with osteosarcoma and fibroblast cell exosomes for
24 h. (A) Proliferation and (B) migration were analyzed using the IncuCyte S3 Live-Cell
Analysis system.
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5.9: Assessment of extracellular communication between metastatic cells and
non-metastatic osteosarcoma cells

Exosomes, both in vitro and in vivo have been shown to modulate cellular
signaling within the tumor microenvironment. Based on previous data that suggested
an integral role for mir20a and FAS in osteosarcoma metastasis, it was necessary to
further investigate this phenomenon and how it might be mediated by an exosomal
signaling pathway. First, we assessed both the mRNA and protein expression levels of
the FAS receptor in the metastatic LM7 cell lines, as well as its parental cell line
SAOS2. These data were consistent with previously published findings in that SAOS2
cells had high mRNA and protein expression levels of FAS, while LM7 was the
opposite, showcasing lower levels of both mRNA and protein levels of FAS (Figure 30).
Next, we evaluated levels of mir20a in both cell lines, and found that LM7 cells had
significantly higher levels of mir20a as compared to SAOS2 cells (Figure 31A). Next,
exosomes were collected from both LM7 and SAOS2 cells, and mir20a levels were
found to be significantly increased in LM7 cell exosomes as compared to SAOS2
exosomes (Figure 31B). FAS mRNA levels were undetectable in both exosome
samples (data not shown). In order to assess whether SAOS2 cells could uptake
metastatic LM7 cell exosomes, exosomes were collected and stained with a specific
plasma membrane dye and incubated with SAOS2 cells for twenty-four hours. Results
indicated that SAOS2 cells could rapidly uptake LM7 cell exosomes (Figure 32). Next,
the mRNA and protein levels of FAS in SAOS2 were assessed during a 48hr time
course with LM7 cell exosomes. FAS mRNA levels in the SAOS2 cells were shown to
be significantly decreased over the 48-hour time period (Figure 33A). Once it was
established that LM7 cell exosomes could modulate FAS receptor expression in
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SAOS2 cells, we investigated whether this would have an effect on SAOS2 cell survival
in response to FAS-L. We found that LM7 cell exosome pre-treatment resulted in a
significant increase in SAOS2 cell viability when exposed to FAS Ligand as measured
by MTT assay (Figure 33B).
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Figure 30 - LM7 cells contain significantly decreased levels of the FAS receptor
than its parental counterpart SAOS-2 cells. (A.) Osteosarcoma cells were cultured
overnight. The cells were harvested, total RNA collected, and cDNA conversion
performed. B-actin was used as a loading control. mRNA expression of FAS was
quantitated by qPCR. (B & C.) FAS receptor expression was assessed by flow
cytometry. B-actin was used as an internal control. * represents a p value < 0.05 and
was considered significant by student’s t-test.
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Figure 31 - Metastatic exosomes from LM7 cells contain mir20a. (A.) Expression
levels of mir20a was evaluated in SAOS2 and LM7 cells via qPCR. (B.) Exosomes
were extracted via ultracentrifugation and mir20a levels were assessed by qPCR. U44
was used as an internal control. * represents a p value < 0.05 and was considered
significant by student’s t-test.
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Figure 32 - SAOS2 cells can uptake LM7 cell exosomes. LM7 cell exosomes were
extracted via ultracentrifugation and then labeled with Cell Tracker CM-DiI red
fluorescent dye. SAOS2 were cultured overnight and then treated with labeled
osteosarcoma cell exosomes for 24 h. Both fluorescent and bright field images were
collected using the Nikon Eclipse Ti de-convolution inverted bright field and fluorescent
microscope at 60x under oil immersion. Osteosarcoma cell exosomes are shown in red
and DAPI in blue.

111

Figure 33 - Metastatic exosomes from LM7 cells deplete FAS mRNA levels in
SAOS2 cells and cause a significant increase in cell viability when exposed to
FAS-ligand. (A.) SAOS2 cells were treated with 50ugs of LM7 cell exosomes and RNA
was collected over a period of forty-eight hours. FAS receptor expression was
evaluated by qPCR. (B.) SAOS2 cells were pretreated with 50ugs of LM7 cell
exosomes for twenty-four hours, then exposed to FASL for twenty-four hours. Cell
viability was then assessed by MTT assay. * represents a p value < 0.05 and was
considered significant by student’s t-test.
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CHAPTER SIX: GLOBAL DISCUSSION AND FUTURE DIRECTIONS

6.1: Introduction

Osteosarcoma is a heterogeneous disease that impacts a number of pediatric
and elderly patients each year. Survival rates have plateaued in the last fifty years,
showcasing an increasing clinical need to further understand this disease [4, 6].
Patients diagnosed with non-metastatic osteosarcoma that are treated with a
combination of surgery and neo-adjuvant chemotherapy have a curative rate of seventy
percent [3]. Metastasis occurs almost exclusively to the lungs and once this occurs,
patient survival rates remain dismal at less than twenty percent [4, 6]. Therefore, it is
important to study and fully understand this disease in order to best improve patient
outcome. Recently, the tumor microenvironment has been suggested to play
increasingly important roles in both cancer development and progression [37, 129]. The
tumor microenvironment is a complex structure composed of a variety of cell types and
factors, including immune cells [40]. In osteosarcoma, macrophages have been shown
to be an important factor in patient survival and growing evidence have suggested that
macrophage phenotype also plays a role in tumor progression and metastasis. TAMs
are commonly polarized to the M2-subtype in osteosarcoma [105]. In other cancers,
macrophage phenotype is modulated by a variety of factors including exosomes, which
are small extracellular vesicles that are integral to cell to cell communication [120, 186,
187, 191, 214, 231]. The goal of this dissertation was to investigate the mechanisms of
exosomal communication in osteosarcoma metastasis. My hypothesis was that the
exosomal cargo of a metastatic osteosarcoma cell could modulate cellular signaling
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within macrophages, thereby causing the development of an M2 tumor-promoting
phenotype. I devised two specific aims in order to investigate this hypothesis which
were to (i) characterize the changes in macrophage function in response to metastatic
exosome uptake in vitro and to (ii) determine the mechanism by which metastatic
osteosarcoma exosomal cargo modulates alveolar macrophage function in vitro. I
found that metastatic osteosarcoma cell exosomes can inhibit macrophage functions
such as phagocytosis, efferocytosis and macrophage-mediated tumor cell killing. In
addition, I found that metastatic osteosarcoma cell exosomes induced an M2-like
phenotype in macrophages, including increased secretion of TGFB2. Lastly, I found
that inhibition of TGFB2 reversed the suppressive activity of metastatic osteosarcoma
cell exosomes and restored normal macrophage phagocytic function. In this chapter, I
will discuss the limitations and pitfalls of this study, the possible future implications of
this work and I will also address future studies that should be performed.

6.2: General Discussion

Our study has suggested that extracellular communication within the tumor
microenvironment resulted in the inhibition of macrophage function through the
production of TGFB2. TGFB2 plays an important role in tumor associated macrophage
behavior and may be a viable therapeutic target in the treatment of metastatic
osteosarcoma patients [31, 222]. TGFB is an important immunosuppressive cytokine
that regulates both the generation and effector functions of a wide variety of immune
cells [222]. TGFB controls the adaptive arm of the immune system by inhibiting the
generation and function of effector T cells as well as antigen presenting dendritic cells
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[222]. Additionally, TGFB also directly promotes the expansion of T-reg cells [222].
TGFB also controls the innate arm of the immune system by inhibiting natural killer
cells, as well as modulating the behavior of neutrophils and macrophages [222]. TGFB
is a powerful cytokine that exerts effects beyond the immune system that include the
regulation of cell growth, differentiation, apoptosis, cell motility, angiogenesis as well as
extracellular matrix production [222, 226]. In the context of cancer, TGFB plays major
roles in tumor progression, the epithelial to mesenchymal transition, angiogenesis,
cancer cell migration and invasion, resistance, and metastasis [222, 226].
TGFB signaling is activated when TGFB binds to the transforming growth factor
beta receptor-2 (TBRII) which initiates a complex that involves the participation of
transforming growth factor beta receptor-3 (TBRIII) in order to facilitate ligand-receptor
binding [226]. Transforming growth factor beta receptor-1 (TBRI) is then recruited to the
TBRII/TBRIII complex and functions as a serine/threonine kinase which phosphorylates
SMAD2 and SMAD3. The phosphorylated SMAD2 and SMAD3 combine to form a
complex with SMAD4 that then trans-locates to the cellular nuclear to interact with a
variety of transcriptional factors that ultimately lead to the modulation of the cell’s
response [226]. TGFB is also capable of signaling independently of SMAD (noncanonically) through several different pathways which include AKT, MAP kinase, PI3K,
ERK, JNK, and p38. TGFB signaling can be negatively regulated by SMAD6 and
SMAD7 which interfere with the phosphorylation of SMAD2 and SMAD3 [226]. Current
targets against TGFB signaling include antibodies that block TGFB and its interaction
with its receptor, antisense molecules that target TGFB synthesis, as well as kinase
inhibitors or aptamers that interfere with the function of downstream SMAD proteins
[226]. There are three isoforms of TGFB (TGFB1, TGB2, TGFB3), but the roles of
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these isoforms are not well understood, especially in the context of macrophage
behavior [222, 226]. Osteosarcoma cells have been shown to express all three
isoforms of TGFB both within the cytoplasm of the cell as well as in the extracellular
stroma in the primary tumor, but this has not been investigated in the context of
metastatic lesions [232]. When TGFB2 was inhibited through the use of an antisense
oligonucleotide, lung metastases of breast and kidney tumors were reduced in part
through the re-education of M2 macrophages to the M1 antitumor phenotype which
suggests that TGFB2 plays an important role in macrophage phenotype [227].
Additionally, TGFB2 was found to be the principal cytokine that controlled microglia and
macrophage phagocytic function, rather than TGFB1 [228]. Our studies suggested that
metastatic osteosarcoma cell exosomes or factors within the metastatic osteosarcoma
cell exosomes induce TGFB2 signaling within alveolar macrophages and thereby
modulate macrophage-mediated phagocytosis, efferocytosis, and tumor cell killing. The
specific targeting of TGFB2 may improve macrophage M1 function and response to
treatment by redirecting tumor-associated macrophages from the M2 to the M1
phenotype.
TGFB2 is a current target of interest in cancer and there are clinical trials
targeting pediatric populations including Ewing’s sarcoma as well as other solid tumors
currently enrolling using Vigil, a biological composed of autologous tumor cells
harvested from the patients, a plasmid encoding for GM-CSF, as well as a bi-functional
short hairpin RNA that specifically inhibits the expression of furin, a critical convertase
responsible for the production of TGFB1 and TGFB2 (NCT03842865). Other
therapeutics used in recently completed clinical trials include AP 12009 (trabedersen),
a phosphorothioate antisense oligodeoxynucleotide specific to TGFB2 (NCT00844064)
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and a TGFB2 antisense-GMCSF gene modified autologous tumor cell vaccine
(NCT00684294).
Another target that warranted investigation in this study was IL10. IL10 is a
potent homeostatic regulator of the anti-inflammatory response and has been shown to
display immunosuppressive activities toward various components of the immune
system [233]. Its major physiological function is to constrain macrophage activity in
response to pathogens and their products [230]. IL10 regulates inflammation in both
acute and chronic settings [230]. IL10 mRNA and protein have been found in a variety
of cancer cell lines as well as freshly excised human tumors [76, 77, 234, 235]. IL10
can be secreted into the tumor microenvironment by both tumor cells and tumorassociated macrophages [77, 236]. Furthermore, IL10 constrains inflammation-induced
macrophage phagocytosis of healthy normal cells [75]. Our data initially suggested that
metastatic osteosarcoma cell exosomes or factors within the metastatic osteosarcoma
cell exosomes induce IL10 signaling within alveolar macrophages. Based on our data,
we hypothesized that the activated signaling mechanism induces the activation of IL10
receptor signaling, followed by the activation and phosphorylation of JAK1 and STAT3,
which then induces further transcription of STAT3. Upon further evaluation of IL10
though, we found that the secretion of IL10 was not significantly different between MHS
cells treated with K7M3 or K7 exosomes. IL10 secretion levels were significantly
elevated in MHS cells treated with DLM8 exosomes as compared to DUNN exosomes,
so we decided to further investigate IL10 signaling by assessing STAT3. STAT3 is an
important molecule that can mediate tumor-induced immune suppression and acts as a
critical brake to immune signaling within the tumor microenvironment [237]. STAT3
expression also negatively regulates Th1-type inflammation [238]. Inhibition of STAT3
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increases the amount of pro-inflammatory mediators such as cytokines and nitric oxide
in macrophages and neutrophils [238]. Additionally, disruption of STAT3 signaling in
macrophages led to antigen-specific activation of CD4+ T cells in response to a
tolerogenic stimulant and disrupted antigen-specific T-cell anergy in vivo [239]. Finally,
blocking STAT3 signaling activates antitumor immune responses in vivo [240]. In our
initial observations, STAT3 mRNA expression levels were significantly elevated in
alveolar macrophages exposed to metastatic exosomes. When we evaluated protein
levels of STAT3 in alveolar macrophages exposed to metastatic exosomes, we found
that phospho-STAT3 levels were inhibited similarly to M2 macrophages (MHS cells
exposed to IL4/IL13). This suggested that IL10 signaling was not responsible for the
decreased function in alveolar macrophages. It is possible that the increased gene
expression in STAT3 was due to the delivery of mRNA within the metastatic exosomes.
It is also possible that there are post-transcriptional mechanisms in place that inhibit the
translation of STAT3 mRNA. It is unclear what role STAT3 plays in alveolar
macrophage phagocytosis, as well as M2 macrophage behavior and warrants further
investigation.
We also performed RNA sequencing in order to gain a more comprehensive
understanding of the signaling changes that may occur in alveolar macrophages
exposed to metastatic and non-metastatic osteosarcoma cell exosomes. There were
several pathways that were downregulated in alveolar macrophages exposed to
metastatic osteosarcoma exosomes such as RAC1, KRAS, RAF1, WTN3, CD101,
CD200R4, SMAD4, LAG3, SMURF2 and TGM4. There were also a number of
pathways that were upregulated in alveolar macrophages exposed to metastatic
osteosarcoma exosomes, such as CD22, VEGFC, CD48, BTNL1, CNTN1, ICAM5,
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TNFSF18, as well as ARG2 and SNAI1. Several viable targets related both to cancer
and immune signaling were revealed as a result of the RNA sequencing, which are
summarized in Table 1, many of which are not at all well understood in the context of
tumor associated macrophages in metastatic osteosarcoma.
ARG2 encodes for arginase, a key enzyme that catalyzes the hydrolysis of
arginine to ornithine and urea and has been associated with M2 macrophages [241243]. M1 and M2 macrophages differ metabolically in that M1 macrophages have the
unique ability to metabolize arginine to nitric oxide while M2 macrophages metabolize
arginine to ornithine [54]. There are two isoforms of the arginase gene, ARG1 and
ARG2 [244]. ARG1 has been more extensively studied and is more closely associated
with M2 macrophages [52]. ARG2 has not been as well studied but its expression
restricts nitric oxide metabolism and its deletion leads to enhanced M1 macrophage
activation [241]. Targeting ARG2 also suppresses macrophage inflammation and is
protective against high fat diet induced hepatic steatosis [243]. Additionally, the
induction of ARG2 in macrophages mediates immune evasion and attenuates inducible
nitric oxide synthase translation in response to Helicobacter pylori [242, 245].The role
of ARG2 in the tumor microenvironment of metastatic osteosarcoma has yet to be
investigated and could be considered a viable target in the repolarization of M2
macrophages to the M1 phenotype. Further studies are warranted to better understand
ARG2 in the context of the metastatic osteosarcoma tumor microenvironment.
SNAI1 is a gene encoding SNAIL that is involved in the induction of the epithelial
to mesenchymal transition, which is a major event that regulates epithelial plasticity in
cancer progression and metastasis [164]. It is also associated with the formation and
maintenance of the embryonic mesoderm, cell growth arrest, as well as cell migration
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and survival [164]. SNAI1 also activates the expression of cytokines such as IL6, IL8,
CCL2 and CCL5 in cancer cells to recruit tumor associated macrophages [246].
Additionally, SNAI1 promotes M2 macrophage polarization [231]. Snail-overexpressing
cancer cells were shown to deliver mir-21-abundant exosomes to macrophages which
induced the M2 phenotype and resulting in increased tumor growth and angiogenesis
[231]. These studies suggest that targeting SNAI1 may be a viable therapeutic target in
the repolarization of M2 macrophages to the M1 phenotype and the data in this study
indicates that it may also be a target in the treatment of metastatic osteosarcoma
patients.
This study also examined extracellular communication between non-metastatic
and metastatic osteosarcoma cells. One component that is important to the process of
metastasis is cancer cell to cancer cell communication. Cancer cells have been shown
to secrete growth factors, cytokines, chemokines as well as extracellular factors into the
tumor microenvironment, which modulates signaling in surrounding cells [37]. In
osteosarcoma, the FAS pathway is extremely important to the metastatic capabilities of
a cancer cell [247]. When the FAS receptor is activated by its ligand (FAS Ligand), a
series of cell signaling pathways are activated, with the end result of apoptosis [248].
Primary osteosarcoma lesions were shown to be highly FAS receptor positive while
pulmonary metastases were shown to be FAS receptor negative [249]. It was also shown
that FAS positive osteosarcoma cells are rapidly cleared from the lung. When the FAS
pathway was corrupted, it was shown that this delays the pulmonary clearance of these
FAS positive cells and enhances their metastatic potential [250].
It is important to note that while the FAS receptor is expressed constitutively
throughout the body, its ligand (FAS Ligand) is not. FAS ligand is expressed in only four
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areas of the body; the small intestine, the anterior chamber of the eye, the testes and the
lung [251, 252]. Since normal lung epithelium expresses FAS ligand, only metastatic
osteosarcoma cells that are FAS receptor negative can escape the process of FASmediated apoptosis and continue to survive and proliferate [23]. The FAS receptor has
been shown to be modulated by a variety of factors, including proteins such as TP53, as
well as miRNAs. miRNAs are small 21 to 23 nucleotide noncoding RNAs that suppress
translation [248]. Expression levels of several members of the miR17-92 cluster,
including mir20a were found to be higher in metastatic low FAS-expressing cells than
parental high-FAS-expressing cells [22]. Conversely, when mir20a was inhibited, FAS
expression was increased. It is possible that cancer cells could be communicating with
each other to down regulate the FAS receptor by means of mir20a encapsulated within
metastatic cancer cell exosomes, which would allow the cells to escape FAS mediated
apoptosis [20, 22, 23]. In this study, we found that exosomes from metastatic LM7 cells
contain higher levels of mir20a than their non-metastatic parental counterpart, SAOS2
cells. We also found that SAOS2 cells could take up LM7 cell exosomes, which resulted
in decreased levels of the FAS receptor over forty-eight hours. Lastly, we also found that
pre-treatment of SAS2 cells with LM7 cell exosomes resulted in a significant increase in
cell viability when exposed to FAS Ligand, thereby providing a protective effect to the
tumor cells from apoptosis. These data suggest that communication between cancer
cells may be important to cancer progression and warrants further study in the context
of metastatic osteosarcoma.
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6.3: Pitfalls and Limitations

There are a number of pitfalls and limitations to this study that should be
considered. The conclusions of this dissertation are based on an in vitro system and it is
reasonable to assume that the observations in this study may or may not equate to what
occurs in vivo. Regardless, this is the first study of its kind to demonstrate that
communication within the osteosarcoma tumor microenvironment may differ depending
on the metastatic status of a tumor cell. While in vivo studies would strengthen the impact
of this dissertation, it is currently unclear how to evaluate the ability of exosomes isolated
from metastatic cells to modulate alveolar macrophage function in vivo. We could inject
metastatic osteosarcoma cell exosomes intravenously in mice, but there are many
shortcomings and pitfalls to this experimental design. If the mice have tumors, exosomes
from the metastases present in the lung may have already induced alterations to
macrophage function and we would see no change in the macrophages harvested from
the tumor nodules before and after exosome infusion. We could look for changes in the
M2 macrophage markers in this context, but those markers only tangentially suggest the
anti-tumor functionality of alveolar macrophages in the presence of osteosarcoma
metastasis. If the mice do not have tumors, it would also be unclear if the injected
metastatic osteosarcoma cell exosomes would have an effect on the resident
macrophages in the lung where there is no tumor. Furthermore, the number of
macrophages in the normal lung is low and therefore isolation of these macrophages
may not be sufficient to investigate function. Additionally, in such an experimental design,
there would be no tumor microenvironment in which to study the cytotoxic behavior of
alveolar macrophages.
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Another limitation of this study was that two different immortalized macrophage
cell lines were investigated in lieu of macrophages derived directly from mice. Primary
alveolar macrophages derived from mice do not readily divide and often result in the
collection of small numbers that are too few to perform the functional assays of this study.
An immortalized alveolar macrophage cell line was used in order to circumvent these
issues. While the limitations of these experiments include the absence of other immune
cells and normal cells that are part of the tumor microenvironment, our goal was to
investigate the hypothesis as to whether exosomes from metastatic but not nonmetastatic cells have the ability to alter macrophage function and the tumor
microenvironment to create an immune privileged area.

6.4: Future Directions
This study examined some of the main functions of alveolar macrophages,
including phagocytosis, efferocytosis and macrophage-mediated tumor cell killing.
Additional studies could also include investigations of other functional changes within
recipient cells that have engulfed metastatic osteosarcoma cell exosomes. I
investigated both proliferation and migration in macrophages exposed to metastatic
osteosarcoma cell exosomes and observed no significant changes, but other pertinent
functions that could be investigated may include invasion, and chemotaxis. Invasion
and chemotaxis can both be investigated using the IncuCyte in order to assess live cell
behavior. I would expect that invasion and chemotaxis of alveolar would be inhibited by
metastatic osteosarcoma cell exosomes while non-metastatic exosomes would be
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enhanced or remain unchanged. An additional measure that may be investigated is the
release of reactive oxygen species by alveolar macrophages in response to metastatic
osteosarcoma cell exosome uptake. Exosomes derived from suppressor T cells
enhance the generation of reactive oxygen intermediates in macrophages, so I would
expect that the suppressive effects of metastatic osteosarcoma might enhance the
secretion of reactive oxygen species by alveolar macrophages while non-metastatic
osteosarcoma cell exosomes would not [253]. Lastly, metabolic changes in alveolar
macrophages exposed to non-metastatic and metastatic osteosarcoma cell exosomes
could be investigated. Since M2 macrophages rely on oxidative glucose metabolism for
sustained energy, it would be pertinent to assess this function in alveolar macrophages
exposed to non-metastatic or metastatic osteosarcoma cell exosomes [54]. I would
expect alveolar macrophages exposed to metastatic osteosarcoma cell exosomes to
show increased levels of oxidative glucose metabolism.
Exosomes have been shown to contain miRNAs, single and double stranded
DNA, RNA as well as protein [129]. It would be very interesting to investigate and
identify on a more comprehensive level what the contents of the exosomes from the
metastatic and non-metastatic cell lines may consist of. Future studies could include
genomic and proteomic profiling of metastatic and non-metastatic osteosarcoma cell
exosomes, which may shed light on the specific cargo within an exosome that is
responsible for the functional changes observed in this study. Additional studies could
also be performed profiling the changes in miRNA and protein expression in alveolar
macrophages exposed to metastatic and non-metastatic osteosarcoma cell exosomes
which would provide a much more comprehensive picture of the complex changes that
occur in response to exosome uptake. In concert, these data could suggest the specific
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mechanism of action in which metastatic osteosarcoma cell exosomes modulate
macrophage function and provide a better understanding of extracellular
communication between osteosarcoma cells and macrophages.
This study suggested that targeting TGFB2 might improve macrophage function
in response to the uptake of metastatic osteosarcoma cell exosomes and because the
inhibition of TGFB2 led to the reduction of lung metastases in breast and kidney tumors
through the re-education of M2 macrophages to the M1 subtype, it is likely that it is a
viable target in the treatment of metastatic osteosarcoma [227]. Future studies should
investigate TGFB2 expression in metastatic lesions within the lung in both patient
tissue as well as metastatic osteosarcoma mouse models. Based on the findings of this
study in combination with what is currently known in the literature, I would expect to find
elevated levels of TGFB2 within metastatic lesions. Using a metastatic osteosarcoma
mouse model, we could inhibit TGFB2 using an anti-TGFB2 antibody and assess the
number of metastatic lesions as compared to an IgG antibody control. In addition,
tissue could be collected and markers of M1 and M2 macrophages could be
investigated. I would expect to find a reduction in the number of osteosarcoma
metastases, a depletion in the observed number of M2 macrophages and an increase
in the number of M1 macrophages through performing this study.
Downstream effectors of TGFB2 signaling should also be assessed. Since
TGFB2 signals through both canonical and non-canonical signaling pathways, these
targets should include SMAD2, SMAD3 and SMAD4 as well as effectors involved in
AKT, MAP kinase, PI3K, ERK, JNK, and p38 cell signaling pathways. Because RNA
sequencing indicated that SMAD4 was depleted following metastatic osteosarcoma cell
exosomes uptake in alveolar macrophages, it is likely that TGFB2 signaling occurs
125

through a non-canonical pathway. It is currently unclear as to how this signaling might
be occurring, but further study into these cell signaling mechanisms could elucidate
novel therapeutic opportunities that might improve the outcome of patients with
metastatic disease to the lung.
Through performing RNA sequencing on alveolar macrophages exposed to nonmetastatic and metastatic osteosarcoma cell exosomes, a number of other targets
were elucidated in this study. Additional analyses could investigate the role of ARG2 in
macrophage function in the metastatic osteosarcoma tumor microenvironment. This
study found that ARG2 expression levels were significantly elevated in alveolar
macrophages exposed to metastatic osteosarcoma cell exosomes. Previous studies
have suggested that ARG2 plays a role in macrophages polarization [241-243, 245]. In
order to elucidate the role that ARG2 might play in alveolar macrophages, ARG2
should be depleted and macrophage function should be investigated. Phagocytosis,
efferocytosis, macrophage-mediated tumor cell killing and metabolic assays measuring
oxidative glucose metabolism should be performed. Because ARG2 has been
associated with M2 polarization, I would expect that the inhibition of ARG2 would lead
to increased phagocytosis, increased macrophage-mediated tumor cell killing as well
as a decrease in oxidative metabolism due to the shift in macrophage polarization to a
more M1-like phenotype.
Another viable target to assess would be the role of SNAI1 in the metastatic
osteosarcoma tumor microenvironment. This study showed that SNAI1 expression is
elevated in alveolar macrophages exposed to metastatic osteosarcoma cell exosomes.
CD47 is a direct target of SNAI1 and that its inhibition leads to enhanced phagocytosis
of breast cancer cells that are undergoing the epithelial-to-mesenchymal transition
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[254]. Additionally, SNAI1 is often elevated in metastatic lesions and is associated with
the recruitment of M2-like macrophages, as well as the induction of an M2-like
phenotype [231]. Furthermore, SNAI1 expression has been shown to induce
osteosarcoma invasion and metastasis [255]. SNAI1 expression should be investigated
in non-metastatic and metastatic osteosarcoma cells and their exosomes. I would
expect SNAI1 levels to be elevated in metastatic osteosarcoma cells and their
corresponding exosomes as compared to their non-metastatic parental cell lines.
Additionally, SNAI1 expression should be depleted in alveolar macrophages and
macrophage functions such as phagocytosis, efferocytosis and macrophage-mediated
tumor cell killing should be investigated. Furthermore, markers of the M1 and M2
phenotype should be assessed to investigate the role that SNAI1 plays in alveolar
macrophages since this has not been performed in this specialized tissue resident
population before. I would expect that the inhibition of SNAI1 would lead to an increase
in M1 markers, a decrease in M2 markers, and an increase in macrophage tumor
suppressive functions, which would suggest it may be a viable treatment option to
repolarize M2 macrophages to the M1 phenotype within the tumor microenvironment
and improve the outcome in patients with metastatic disease.
There are a number of additional targets that warrant investigation in the
metastatic osteosarcoma tumor microenvironment that were indicated in the RNA
sequencing performed as a result of this study. RAC1 was shown to be depleted in
macrophages exposed to metastatic osteosarcoma cell exosomes and has been
suggested to play a role in the modulation of efferocytosis in concert with RHOA [220].
KRAS was downregulated in macrophages exposed to metastatic osteosarcoma cell
exosomes and it has been shown that delivery of KRASG12D exosomes to macrophages
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causes the repolarization to an M2-like phenotype in the context of pancreatic cancer
[256]. Additionally, high MEK-ERK activation promotes M1 polarization [257]. CD22
was also shown to be elevated in macrophages exposed to metastatic osteosarcoma
cell exosomes and the blockade of CD22 restores microglial phagocytosis in the aging
brain [258]. LAG3 was depleted in macrophages exposed to metastatic osteosarcoma
cell exosomes and its expression on T cells has been correlated with the inhibition of
macrophage function [259, 260]. VEGFC was elevated in macrophages exposed to
metastatic osteosarcoma cell exosomes and has been suggested to recruit tumor
associated macrophages in non-small cell lung cancer metastasis in a paracrine
signaling associated manner [261]. SMURF2 was found to be downregulated in
macrophages exposed to metastatic osteosarcoma cell exosomes and is
downregulated in M2 macrophages [244]. There are a number of other genes related to
immune or cancer cell signaling pathways that were either elevated or inhibited in
alveolar macrophages in response to metastatic osteosarcoma cell exosomes which
can be found in Table 1. The roles of these genes are not understood, especially in the
context of metastatic osteosarcoma. Further study is warranted to clarify the roles of
these genes within the metastatic osteosarcoma tumor microenvironment.
The translational impact of this dissertation could extend into the clinic and with
further investigation might improve the outcome of patients with metastatic disease.
Currently, a number of different antibodies are being actively used in the clinic such as
anti-PD-1, anti-PDL1, and anti-CTLA4. This study brings a new target to light in TGFB2
in osteosarcoma patients with metastatic disease. It might be possible to inhibit TGFB2
using a neutralizing antibody, which would repolarize macrophages to the M1
phenotype and allow for the generation of a more tumor-suppressive
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microenvironment. It is possible that the size of the lung tumors in osteosarcoma
patients may reduce in size and improve patient survival. The use of anti-TGFB2 could
prove beneficial to osteosarcoma patients that present with metastatic disease,
especially in combination with multi-agent chemotherapy.
A diverse composition of immune cells, mesenchymal cells as well as a wide
variety of acellular constituents contribute to the functional heterogeneity of tumors. In
addition to this complicated network, it is now understood that exosomes play a key
role within the tumor microenvironment. This study examined the mechanisms of
exosomal communication between osteosarcoma cells and alveolar macrophages and
revealed a novel role for metastatic osteosarcoma cell exosomes in the immune
suppression of alveolar macrophages. Future studies could examine exosomal
communication between other cells in the tumor microenvironment. While cancer cells
are known to excrete large numbers of exosomes, normal cells excrete exosomes as
well. The vast majority of exosome research suggests the tumor-promoting effect of
cancer cell derived exosomes, but stromal-derived exosomes may have different and
perhaps opposite functions from cancer cell derived exosomes. Exosomal
communication between cells is a young and understudied field that requires much
more intensive studies in order to better understand the tumor microenvironment so
that we may improve the treatment and outcome of our patients, especially those with
metastatic disease.

129

CHAPTER SEVEN: METHOLODY

Cell culture
Murine alveolar macrophage cell line MHS and human monocyte THP1 cells
(American Type Culture Collection, ATCC) were maintained in RPMI 1640 medium
(Gibco, 11875-093) supplemented with 10% heat-inactivated fetal bovine serum (FBS)
in a 37°C, 5% CO2 atmosphere. Murine osteosarcoma cell lines (non-metastatic K7
and Dunn; metastatic K7M3 and DLM8) and murine fibroblast cell line NIH-3T3 were
maintained in Dulbecco modified essential medium (Corning, SH30243.01)
supplemented with 10% heat-inactivated FBS in a 37°C, 5% CO2 atmosphere. Human
osteosarcoma cell lines (non-metastatic SAOS2 and metastatic LM7) were maintained
in Dulbecco modified essential medium (Corning, SH30243.01) supplemented with
10% heat inactivated FBS in a 37°C, 5% CO2 atmosphere.

Isolation of exosomes
Osteosarcoma and fibroblast cell cultures were serum starved for 48-72 h and
the conditioned media were collected and subjected to centrifugation at 800 ´ g at
room temperature for 5 min and then to centrifugation at 2,000 ´ g at room temperature
for 10 min. The supernatant was then filtered through a 0.22-µm vacuum filter (Corning,
431153). The filtered supernatant was then subjected to ultracentrifugation at 100,000
´ g at 4°C for 2 h using an Optima XE-90 preparative ultracentrifuge (Beckman Coulter,
Pasadena, CA). The exosome pellet was washed in 35 mL of phosphate-buffered
saline solution (PBS) and underwent a second ultracentrifugation at 100,000 ´ g at 4°C
for 2 h. Next, the exosome pellet was resuspended in 210 µL of PBS. Exosome
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concentration was determined by the BCA assay (Pierce, 23227) with bovine serum
albumin as a standard. All experiments were conducted with an exosome treatment
concentration of 50 µg/mL. Exosome size was quantified by nanoparticle tracking
analysis using the NanoSight NS300 (Malvern Panalytical, Malvern, United Kingdom).

Figure 34 – Ultracentrifugation exosome isolation method.

Real-time qPCR
Total RNA was collected from cells using the RNeasy Mini Kit (Qiagen, 74104).
RNA was reverse transcribed into cDNA using qScript cDNASuperMix (Quanta
Biosciences, 95047-100). Quantitative RT-PCR analyses of murine IL10 (forward: 5´GCTCTTACTGACTGGCATGAG- 3´; reverse: 5´- CGCAGCTCTAGGAGCATGTG- 3´);
TGFB2 (forward: 5´- CTTCGACGTGACAGACGCT- 3´; reverse: 5´GCAGGGGCAGTGTAAACTTATT- 3´); CCL22 (forward: 5´AGGTCCCTATGGTGCCAATGT- 3´; reverse: 5´- CGGCAGGATTTTGAGGTCCA- 3´);
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CXCL9 (forward: 5´- TCCTTTTGGGCATCATCTTCC- 3´; reverse: 5´TTTGTAGTGGATCGTGCCTCG- 3´); CXCL10 (forward: 5´CCAAGTGCTGCCGTCATTTTC- 3´; reverse: 5´- GGCTCGCAGGGATGATTTCAA3´); IL1B (forward: 5´- CCAGCTTCAAATCTCACAGCAG- 3´; reverse: 5´CTTCTTTGGGTATTGCTTGGGAT- 3´); TNFa (forward: 5´GCCTCTTCTCATTCCTGCTTG- 3´; reverse: 5´- CTGATGAGAGGGAGGCCATT- 3´);
FAS (forward: 5´- GCTGGTGAGTGTGCATTCCTTGAT - 3´; reverse: 5´GCCAATTCTGCCATAAGCCCTGTCC - 3´); Beta-actin (forward: 5´GGCTGTATTCCCCTCCATCG - 3´; reverse: 5´- CCAGTTGGTAACAATGCCATGT 3´); and histone HF3FA (forward: 5´- TGTGGCCCTCCGTGAAATC-3´; reverse: 5´GCGTGCTAGCTGGATGTCTT-3´) were carried out in triplicate in a 384-well plate
using a Lightcycler 480 (Roche Applied Sciences, Indianapolis, IN). The data were
normalized to the housekeeping gene histone Hf3fa and then the fold-differences were
calculated using the formula f = 2(d), where f = fold-difference in specific gene
expression and d = cycle number difference between compared sources of mRNA (i.e.,
corrected for differences in histone). Melting curves were also analyzed for specificity of
PCR product amplification.

RNA sequencing
Total RNA was collected from cells using the RNeasy Mini Kit (Qiagen, 74104).
RNA quantity and quality were assessed using a Qubit 2.0 Fluorometer (Thermal
Fisher Scientific) and a Bioanalyzer 2100 (Agilent Technologies). The RNA samples
were prepped for sequencing using the TruSeq Stranded Total RNA Gold kit (Illumina
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RS-122-2303). The quantity and quality of the prepared libraries were assessed using
the Tape Station 2200 D1000 assay (Agilent Technologies) and the QuantStudio 6 Flex
Real time PCR system (Applied Biosystems). The RNA libraries were then sequenced
on a HiSeq 3000 (Illumina) using paired end sequencing for 75 cycles.

Reagents, Antibodies and Immunoblot Analysis
Monoclonal antibodies were purchased from Abcam (Boston, MA) for
Calreticulin (ab92516), HSP90B1 (ab3674), CD9 (ab92726) and Beta-actin (ab8226). A
monoclonal antibody for CD81 was purchased from Santa Cruz Biotechnology (sc166029). For immunoblotting, cells were lysed in RIPA buffer (ChemCruz, sc-24948)
contained protease pellet (Roche, 04693159001) while exosomes were lysed in 8M
urea 2.5% SDS buffer contained protease pellet. Protein concentrations were
determined using the BCA assay (Pierce, 23225) with BSA as a standard. Thirty
micrograms of total cellular or exosomal protein were loaded per lane and separated by
SDS-PAGE. After transfer at 4C, the nitrocellulose membrane (Invitrogen, Carlsbad,
CA) was blocked with either 5% nonfat dry milk or 5% BSA in Tris-buffered saline (pH
8.0) prior to the addition of primary antibodies and followed with peroxidase-conjugated
anti-mouse IgG or anti-rabbit IgG. Protein bands were detected with using a Bio-Rad
Chemi-Doc image station with UV-light box (Hercules, CA). An ELISA kit for mouse
IL10 was purchased from R&D Systems (M1000B) and performed per the
manufacturer’s instructions. A Bio-Plex Pro™ TGF-β 3-plex Assay (171W4001M) was
purchased from Bio-rad Technologies and performed according to the manufacturer’s
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instructions. A neutralizing TGFB2/1.2 Antibody was purchased from R&D Systems
(AF-302-NA) and used at a concentration recommended by the manufacturer.

Immunogold labeling of whole mount exosomes
Samples were placed on formvar-carbon coated mesh nickel grids and treated
with poly-L-lysine for 1 h. Excess sample was blotted with filter paper and allowed to
dry. Grids were washed with PBS and then incubated with CD9 antibody overnight.
Grids were washed and then incubated with secondary gold antibody for 2 h at room
temperature. The grids were washed and then negatively stained with Millipore paperfiltered aqueous 1% uranyl acetate for 1 min. The stain was blotted dry with filter paper
and the samples were allowed to dry. Samples were then examined in a JEM 1010
transmission electron microscope (JEOL, USA Inc., Peabody MA) at an accelerating
voltage of 80 kV. Digital images were obtained using the AMT imaging system
(Advance Microscopy Techniques Corp., Danvers, MA).

Confocal microscopy
Osteosarcoma and fibroblast exosomes were labeled with Cell Tracker CM-DiI
red dye (Invitrogen, C7000). Briefly, exosomes were incubated with 1 micromole of dye
at 37°C for 5 min. Exosomes were then incubated at 4°C for 15 min. The labeled
exosomes were diluted in 35 mL of PBS and subjected to ultracentrifugation at 100,000
´ g at 4°C for 2 h. The exosome pellet was washed in 35 mL of PBS and a second
ultracentrifugation was performed at 100,000 ´ g at 4°C for 2 h. Next, the exosome
pellet was resuspended in 210 µL of PBS. MHS cells were plated on cell culture slides
(Corning, 53106-304) and treated with labeled osteosarcoma or fibroblast exosomes.
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The slides were imaged after 24 h using the Nikon Eclipse Ti de-convolution inverted
bright field and fluorescent microscope (Nikon Instruments, Melville, New York). PBS
treated MHS cells were used as control.

IncuCyte exosome uptake assay
Exosomes were prepared exactly as for confocal microscopy. MHS cells were
seeded in a 96-well plate and treated with labeled exosomes. The plate was imaged
using the IncuCyte S3 Live-Cell Analysis System (Essen Biosciences, Ann Arbor, MI).
PBS treated MHS cells were used as control.

IncuCyte phagocytosis/efferocytosis assay
MHS cells or THP1 cells were seeded in a 96-well-plate and cultured overnight.
THP1 cells were activated with PMA (150 ng/mL) for twenty-four hours. To evaluate
phagocytosis, osteosarcoma cells and fibroblasts were cultured separately and then
labeled with the IncuCyte pHrodo red labeling reagent (Essen Biosciences, 4649) per
the manufacturer’s instructions. The pHrodo-labeled cells were added to the MHS cells
and then imaged and analyzed using the IncuCyte S3 Live-Cell Analysis System. To
evaluate efferocytosis, the osteosarcoma cells and fibroblasts were treated with
gemcitabine (SAGENT Pharmaceuticals, 234-10), which induces apoptosis. The doses
of gemcitabine used were cell line–specific and chosen from analysis of live-cell
imaging over a time course of 48 h using the IncuCyte S3 Live-Cell Analysis System.
Additionally, viability was measured using the Vi-Cell XR automated cell viability
analyzer (Beckman Coulter, Pasadena, CA). Doses of gemcitabine were chosen so
that treated cells were still viable at 24 h but apoptotic at 48 h; doses were as follows:
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K7M3, 25 µg/mL; K7, 0.78 µg/mL; DLM8, 0.31 µg/mL; Dunn, 0.08 µg/mL; 3T3, 0.31
µg/mL.

IncuCyte macrophage-mediated tumor cell killing assay
Osteosarcoma cells and fibroblasts were seeded in a 96-well-plate and cultured
overnight. The cells were labeled with IncuCyte Caspase 3/7 Green Apoptosis Reagent
(Essen Biosciences, 4440). MHS or THP1 cells were added to the labeled
osteosarcoma cells or fibroblasts, and the cells were imaged and analyzed using the
IncuCyte S3 Live-Cell Analysis System.

MTT Assay
SAOS-2 cells were seeded in a 96 well plate. The cells were treated with LM7
cell exosomes for twenty-four hours. Next, the cells were treated with FAS Ligand for
twenty-four hours. During the last 2 h of incubation, 40 ml MTT (2.5 mg/ml; Sigma) was
added into each well (0.42 mg/ml). At the end of the incubation, the MTT was removed
and the cells were lysed with dimethylsulfoxide (DMSO). Absorbance was measured at
570nm using a 96-well microtiter plate reader (Biotek, Winooski, VT).

Flow Cytometry
Cultured cells were washed with 1× PBS once, trypsinized, and resuspended in
1× PBS containing 0.5% FBS. Cells were stained with phycoerythrin (PE)-conjugated
FAS antibody (BD Pharmingen, 555674) or PE-conjugated control IgG (BD
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Pharmingen, 555749) for 30 minutes at 4°C in the dark and examined with a LSR
Fortessa FACS flow cytometer (BD Biosciences, San Jose, CA).

TaqMan qPCR
Total RNA was reverse transcribed using specific miRNA primers. The resulting
cDNAs were amplified by PCR using TaqMan MicroRNA Assay primers with the
TaqMan Universal PCR Master Mix and analyzed with the iQ5 Real-Time PCR
detection system (Bio-Rad Laboratories, Hercules, CA). RNU44 was also measured as
an internal control.

Statistical analysis
The Student t-test was used to compare the ratios of gene expression, protein
secretion and the measures of macrophage phagocytosis, efferocytosis, and
macrophage-mediated tumor cell killing. Each experiment was conducted at least twice
using three replicates per sample. A p value of > 0.05 was considered significant.
Microsoft Excel was used to analyze the above data.
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